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1.1. Chronic pancreatitis 
 
Chronic pancreatitis (CP) is a progressive inflammatory disorder. A key characteristic of the 
condition is severe recurrent abdominal pain. In this introduction the definition and 
classification of CP with the complications and treatment strategies will be briefly described. 
Furthermore, the epidemiology of the disease and the recent ideas about the aetiology, with 
special emphasis on the genetic predisposition for CP, will be discussed.  
 
1.1.1. Definition and classification 
 
Chronic pancreatitis in adults has been defined as a progressive inflammation of the pancreas, 
characterised by irreversible morphologic changes, causing typically pain and eventually also 
results in impairment of exocrine and/or endocrine functions [1].  
Widely used classification systems, such as the Marseille classification of 1963 [2] with 
revisions in 1984 [3] and 1988 [1] or the Cambridge classification of 1984 [4], may help 
distinguish acute from chronic pancreatitis. Chronic pancreatitis requires permanent 
histological irregularities, often associated with persistent clinical and functional impairment, 
while acute pancreatitis leads to clinical, histological and functional resolution of disease once 
the causing factor has been removed. However these classifications do not distinguish the 
different forms of chronic pancreatitis.  
In the investigations depicted in this thesis, we classified the CP patients in three main 
categories, namely: hereditary CP (HCP), alcoholic CP (ACP) and idiopathic CP (ICP).  HCP 
is diagnosed on the basis of two first-degree relatives or three or more second-degree relatives 
in two or more generations, who suffered from recurrent acute pancreatitis or chronic 
pancreatitis for which there was no precipitating factor. ACP is diagnosed in patients who 
consumed more than 60 g (females) or 80 g (males) of ethanol per day for more than two 
years. Patients are classified as having ICP when precipitating factors such as alcohol abuse, 
trauma, medication, infection, metabolic disorders and/or a positive family history are all 
absent. 
 
1.1.2. Treatment and complications 
 
The treatment of CP is depended on the stage of the disease and the different complications 
and is generally focused on pain. The pain therapy is based on the knowledge of the various 
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causes of pain. Endoscopy is usually the first choice for bile duct or pancreatic duct strictures, 
followed by surgery. Exocrine insufficiency is treated by porcine pancreatic extracts and 
endocrine insufficiency by insulin. Various imaging procedures such as ERCP, MRCP, 
sonography and CT are used for getting a clear diagnosis and the planning of therapeutic 
strategies [5]. Because of the pancreatic insufficiency some patients develop white bulky fat 
defecation, weight loss and insulin-dependent diabetes mellitus. A frequent complication of 
pancreatic inflammation is the formation of pancreatic pseudocysts, which may rupture, 
become infected or cause local mechanical obstruction. Other complications include 
calcifications and necroses, with the risk of infection of the pancreas. A late complication of 
CP is pancreatic cancer; the risk for CP patients to develop pancreatic cancer is approximately 
50 times higher as compared to the normal population [6]. 
 
1.1.3. Epidemiology 
 
The incidence of CP appears to be in the range of 3-10 per 100.000 inhabitants [7-9], and is 
gradually increasing [10]. CP is less common than the acute form of the disease, but the 
protracted nature of the condition implies that an increasing incidence is likely to have a 
major impact on prevalence rates in the future. Prevalence rates are now estimated at 13 per 
100.000 habitants. Since the majority of reports confirm alcohol to be the main etiologic agent 
for CP, dissimilarities in alcohol consumption throughout the world reflect the variation in 
incidence rates. Mortality rates have been reported to be in the order of 21-35% at a follow-up 
period of 10 years, from which most die as a result of extrapancreatic malignancy or 
cardiovasculair disease, often due to a combination of smoking and excessive alcohol 
consumption. 
 
1.1.4. Aetiology and risk factors 
 
The exact aetiology of CP is only partially known. Alcohol (ethanol) is being regarded as the 
main cause of CP, in fact alcohol abuse may account for 70-80% of all cases of CP [11,12]. 
However, only 5-10% of heavy drinkers do develop pancreatitis [13], while the mechanism as 
to how alcohol causes CP remains unknown [14]. In addition, other aetiological factors such 
as heredity, smoking, anatomical variations or various metabolic disorders have been 
identified. Nevertheless, these factors alone cannot be disease causing, because only a small 
fraction of individuals exposed to one or more of the above mentioned genetic or 
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environmental factors, ever develop CP. Table 1 lists factors reported to be associated with 
CP according to the TIGAR-O risk factor classification system and categorises patients 
according to the risk factor most strongly associated with CP in a particular patient [9]. 
 
Table 1.1. TIGAR-O Classification System [9] 
Aetiologic risk factors associated with chronic pancreatitis 
 
Toxic-metabolic 
     Alcohol 
     Tobacco smoke 
     Hypercalcemia 
          Hyperparathyroidism 
     Hyperlipidemia  
     Chronic renal failure 
     Medication 
          Phenacetin  
     Toxins 
          Organo-tin compounds 
Idiopathic 
     Early onset 
     Late onset 
     Tropical 
          Tropical calcific pancreatitis 
          Fibrocalculous pancreatic diabetes 
     Other 
Genetic 
     Autosomal dominant 
          Cationic trypsinogen (N29I, R122H) 
     Autosomal recessive 
          CFTR mutations 
          SPINK1 mutations 
          Cationic trypsinogen (codon 16, 22, 23 mutations) 
Autoimmune 
     Isolated autoimmune  
     Syndromic autoimmune  
          Sjögren syndrome-associated  
          Inflammatory bowel disease-associated  
          Primary biliary cirrhosis-associated  
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Recurrent and severe acute pancreatitis 
     Postnecrotic (severe acute pancreatitis) 
     Recurrent acute pancreatitis 
     Vascular disease/ ischemie 
     Postirradiation 
Obstructive 
     Pancreatic divisum 
     Sphincter of Oddi disorders 
     Duct obstructions 
     Preampullary duodenal wall cysts 
     Posttraumatic pancreatic duct scars 
 
 
1.1.5. Pathogenesis 
 
The process leading to CP appears to require the interaction of environmental factors, factors 
that lead to recurrent pancreatic injury eventually in combination with an altered immune 
response, the latter may lead to chronic inflammation and fibrosis [15]. Recent studies 
identified some genetic factors contributing to the mechanism for CP [16], while the 
hypothesis that pancreatitis may result from pancreatic autodigestion was made for more than 
a century ago [17]. An inappropriate intrapancreatic activation of zymogens by trypsin may 
initiate the inflammatory process. Trypsinogen is secreted by the pancreatic acinar cell [18] 
and it is activated to trypsin within the duodenal lumen by enterokinase, which cleaves an 
eight-aminoacid N-terminal peptide. Trypsin then activates a cascade of digestive enzyme 
precursors. Two different mechanisms prevent inappropriate activation of trypsin within the 
pancreas, before its secretion into the duodenum. First, trypsin is inhibited by serine protease 
inhibitors such as Kazal type 1 (SPINK1). It is thought that this most abundant physiological 
inhibitor of digestive proteases is capable of inhibiting up to 20% of trypsin inside the 
pancreas [19]. Secondly, trypsin itself activates trypsinlike enzymes such as mesotrypsin, 
which readily degrades trypsinogen and other zymogens [20]. Mutations in cationic 
trypsinogen alter certain of its functional properties and lead to a gain of trypsin activity by 
more rapid or efficient intrapancreatic activation of trypsinogen or by an extended activity of 
trypsin due to impaired inactivation or autolysis [21-24]. Trypsin subsequently may activate 
other digestive proteases in a cascade-like fashion and thus mediate acinar cell injury [25]. 
This model was supported by the finding that putative loss-of-function mutations in SPINK1 
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are associated with chronic pancreatitis [26-28]. Thus, gain-of –function mutations in cationic 
trypsinogen and loss-of-function mutations in SPINK1 in a similar way may disturb the 
balance between proteases and their inhibitors within the pancreatic parenchyma (Figure 1.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
TRYPSINOGEN
↓
TRYPSIN
↓ ←→ TRYPSININHIBITORS 
+
-- 
PRO-ENZYMES ENZYMES 
Figure 1.1. Model of chronic pancreatitis 
 
 
1.1.6. Genetic predisposition 
 
Several genetic risk factors for CP have been identified in the recent past. By genetic linkage 
analyses it was discovered that two mutations (N29I and R122H) in the cationic trypsinogen 
gene (PRSS1) were associated with CP [16,29]. More enzyme variants (A16V, D22G, K23R 
and R116C) have been described, but their significance and inheritance pattern is not clear yet 
[21,30-33]. Mutations in SPINK1, an important pancreatic trypsin inhibitor, have been 
associated with CP in children, with ICP as well as with ACP, and have also been found in 
patients with tropical calcific pancreatitis [26,28,34,35]. Furthermore, a variety of mutations 
in the cystic fibrosis transmembrane conductance regulator (CFTR) gene have been identified 
in ICP and ACP patients [36-38]. These findings, although not fully understood yet may lead 
to early diagnostic tools in the future. Genetic variations that may reduce expression or 
activity of biotransformation enzymes are of toxicological and physiological importance and 
are frequently associated with a variety of diseases. There is growing recognition that toxins, 
either of endogenous or exogenous origin, which often are substrates for biotransformation 
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enzymes, are involved as causative agents for CP. As a consequence, interindividual 
differences in detoxification activity for such toxins might also affect the risk of CP [39-45]. 
Likewise, genetic polymorphisms in antioxidative enzymes, leading to a reduced enzyme 
activity, might also be associated with the development of CP, because an imbalance between 
reactive oxygen species (ROS) producing- and ROS-scavenging processes may lead to 
damage of pancreatic acinar cells, initiating auto-digestion of the pancreas [46-50]. Despite 
the fact that some genetic polymorphisms do appear to increase the risk of CP and although 
there is growing evidence suggesting that genetic factors or cofactors are required for the 
development of CP, such factors remain elusive.  
 
1.2. Genes involved in chronic pancreatitis 
 
The following section outlines the most relevant genes and their polymorphic variants that 
may predispose to the development of CP. 
 
1.2.1. Cationic trypsinogen (PRSS1) 
 
The human cationic trypsinogen gene, containing 5 exons is approximately 3.6 kb and is 
located on the long arm of chromosome 7 (7q35) [51]. Cationic trypsinogen plays a central 
role in hydrolysing dietary proteins at lysine and arginine amino acid residues. As outlined 
above, it also plays a key role in activating many other digestive proenzymes [52]. Mutations 
in codon 29 (exon 2) and codon 122 (exon 3) in the cationic trypsinogen gene causes 
autosomal dominant forms of hereditary pancreatitis [16,53]. The R122H mutation, a guanine 
(G) to adenine (A) transition altering arginine to histidine, appears to be the most common 
PRSS1 mutation world-wide [16,30,32, 54,55]. It is hypothesised that the R122H mutation 
alters a trypsin recognition site, which prevents deactivation of trypsin, thus prolonging its 
action within the pancreas [24]. So far it is unclear in which way the N29I mutation, an 
adenine (A) to thiamine (T) transition resulting in asparagine to isoleucine substitution, leads 
to CP [29]. It has been speculated that the N29I mutation would: i) enhances autoactivation of 
trypsinogen, ii) alters the binding of pancreatic secretory trypsin inhibitor, or iii) impairs 
trypsin inactivation by altering the accessibility of the initial hydrolysis site to trypsin. Models 
of the predicted conformational changes in the three dimensional structure of trypsin as a 
result of this amino acid substitution, do confirm these speculations [24]. Several other 
mutations of uncertain significance have been described. A deletion of three nucleotides in the 
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5’untranslated region of PRSS1 at position –28 (-28delTCC) might increase the transcription 
of trypsinogen [31]. In exon 2, the A16V mutation affects the first amino acid of the 
trypsinogen molecule and so directly affects the cleavage side [30]. Two other mutations in 
exon 2, D22G and K23R, show an increased hydrolysis rate of the two mutated peptides, 
indicating that these mutations facilitate cleavage of the activation peptide and thus 
autoactivation of trypsinogen [32,56]. 
 
1.2.2. Serine Protease Inhibitor Kazal Type 1 (SPINK1) 
 
The serine protease inhibitor Kazal type 1 (SPINK1), also known as pancreatic secretory 
trypsin inhibitor (PSTI) is located on chromosome 5 and covers approximately 7.5 kb, 
separated into 4 exons [57]. SPINK1 provides the first line of defence against premature 
trypsinogen activation within the pancreas, because it is capable of inhibiting about 20% of 
the potential trypsin activity, by competitively blocking the active site of trypsin [20]. The 
most frequent mutation in the SPINK1 gene (exon 3) results in an asparagine to serine amino-
acid-change (N34S), which occurs close to the reactive lysine-isoleucine site of SPINK1 and 
may lead to a decreased trypsin inhibitory capacity. Alternatively, N34S may affect the 
processing of the SPINK1 protein, resulting in premature degradation of the inhibitor within 
the endoplasmic reticulum, in analogy with similar mechanisms in other inherited diseases 
such as cystic fibrosis and α1-antitrypsin deficiency [26,58-60]. The N34S mutation is most 
often found in CP patients without a family history; 25%-40% of patients with ICP carry the 
N34S mutation in one or both alleles, and recently frequencies of about 6% were reported in 
ACP patients [26,28,58,61,62]. Furthermore, since the N34S mutation is rather common in 
the general population (approximately 1%-2%) whereas ICP is rare, one may speculate that 
only the combination of N34S and another genetic defect or environmental factors may 
ultimately result in CP. Several other SPINK1 mutations have been described: i) M1T, a 
mutation disrupting the start codon, ii) IVS3+2 T>C is affecting the T at position 2 of the 
splice donor site, iii) L14P in exon 1, leading to the substitution of leucine with proline in the 
signal peptide, iv) additionally, a C-to-T transition is found in the 5’-UTR at position –53, 
which may lead to a new initiating codon and to premature chain termination, and v) a T-to-G 
transition at codon 50 (exon 3) leads to substitution of aspartic acid with glutamic acid 
[26,28]. These latter SPINK1 mutations appear to act as disease modifiers, lowering the 
threshold for initiating CP or possibly may worsen the severity of CP caused by other genetic 
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and/or environmental factors. Moreover, the P55S mutation in exon 3 is thought not to be 
associated with CP [26-28]. 
 
1.2.3. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) 
 
The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, located on the 
long arm of chromosome 7 (7q31), is approximately 250 kb and contains over 4300 
nucleotides, divided into 27 exons, which code for a single protein of 1480 amino acid 
residues [63,64]. Human CFTR plays a central role in ductal bicarbonate secretion into 
pancreatic juice. Over 1000 genetic polymorphisms in CFTR have been reported and many of 
these are very common in the human population. The most common CFTR polymorphism is a 
deletion of three nucleotides in exon 10, abandoning a phenylalanine residue at position 508 
(∆F508). This mutation is present at 66% of all cystic fibrosis chromosomes [65]. The various 
mutations can be divided into five classes of severe (class I, II and III) and mild (class IV and 
V) CFTR mutations [66]. Mutations resulting in defective transcription of mRNA (class I), in 
defective protein processing (class II) and in defective activation, yield little or no functional 
protein, and mutations reducing conductance (class IV) or the amount of protein (class V) 
only decrease the CFTR function. Albeit associations between CFTR mutations and ICP have 
been reported, the pathogenic mechanisms are poorly understood. It has been claimed that 
obstruction of pancreatic ducts due to thickened secretions is involved in the development of 
CP [67,68]. 
  
1.2.4. Biotransformation enzymes 
 
It is suggested that additional genetic factors modify the susceptibility to CP. Xenobiotic-
mediated cellular injury has been hypothesized to be an important pathogenic mechanism in 
pancreatic diseases. Thus, genetic variations that reduce the expression or activity of 
biotransformation or detoxifying enzymes might represent a risk factor for CP [39-45]. The 
major defence against xenobiotic compounds and their metabolites is provided by phase I 
and/or phase II biotransformation reactions. Phase I involves reactions like oxidation, 
reduction and hydrolysis, which changes molecules in such a way that they become more 
hydrophilic and can more readily be conjugated by phase II reactions. The phase I reactions 
are mainly catalysed by a variety of cytochrome P450 monooxygenases (CYP), epoxide 
hydrolases, alcohol dehydrogenases (ADH), aldehyde dehydrogenases (ALDH), esterases and 
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peptidases. Phase II comprises conjugation reactions, mainly catalyzed by glutathione S-
transferase (GST) or UDP-glucuronosyltransferase (UGT) families, which catalyse 
conjugation with glutathione or glucuronic acid, respectively. Other phase II enzymes include 
sulfotransferases and N-acetyl transferases. The end products of the phase II 
biotransformation route are less biologically active and more water-soluble, thereby 
facilitating their excretion via urine or bile. In this thesis we investigated whether genetic 
variations in GSTs, UGTs, CYP2E1 and ADH3, all leading to an altered activity of the 
corresponding enzyme, are associated with the development of CP. 
 
1.2.5. Oxidative stress 
 
Potentially harmful reactive oxygen species (ROS) may be produced as a consequence of 
normal aerobic metabolism [68]. These free radicals are usually removed or inactivated by an 
antioxidant defence, comprising enzymatic as well as non-enzymatic systems [70]. An 
imbalance between antioxidants and (pro)oxidants in favour of the latter is called: oxidative 
stress. Radiation or exposure to alcohol, cigarette smoke, medication, trauma or toxins 
generating free radicals, increase the amount of oxidants. Most cells can tolerate mild 
oxidative stress, which often leads to upregulation of antioxidant defence systems [71]. 
However, severe oxidative stress may lead to lipid peroxidation and may induce damage to 
proteins, carbohydrates, cell membranes and DNA [72]. Important antioxidants belonging to 
the antioxidant defence system are tocopherols (vitamin E), carotenes, vitamin A, ascorbate 
(vitamin C) and glutathione, whereas superoxide dismutase, catalase and glutathione 
peroxidase comprise the most important antioxidant enzymes [73]. A number of diseases are 
associated with oxidative stress and pancreatitis might also be initiated by cellular damage 
due to oxidative stress, resulting in auto-digestion of the pancreas. Genetic variations, 
resulting in variable activity rates of antioxidative enzymes might influence the risk for the 
development of CP [46-50]. We investigated whether genetic polymorphisms of paraoxonase 
1 (PON1) modify the risk for CP. Furthermore, to evaluate the degree of oxidative stress in 
patients with CP, we tried to quantify the oxidative injury in CP patients by measuring 
products of oxidative stress, such as protein carbonyls and TBARS by sensitive assays. 
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1.3. Objectives and outline of the thesis 
 
Despite numerous extensive studies, the actual cause of CP remains elusive. Heavy alcohol 
consumption is the main etiologic factor leading to CP, however several other causes of CP 
have been identified, including several genetic variations in enzymes or proteins associated 
with pancreatic functioning. Mutations in the genes encoding for cationic trypsinogen, 
SPINK1 and CFTR have been the focus of CP research in the past several years. A main 
conclusion of a great number of studies is that the cause of CP is multifaceted and there is 
growing recognition that, in addition to a lifestyle factor, a genetic factor as a cofactor is 
required for the development of CP. Investigations presented in this thesis focus on the link 
between genetics and CP. In chapter 2 the association between genetic polymorphisms in 
glutathione S-transferases and the risk of CP is established. Chapter 3 describes the 
occurrence and frequencies of polymorphic variants in genes encoding alcohol-metabolising 
enzymes in patients with CP as compared to a healthy control group as well an alcoholic 
control group. A study on genetic polymorphisms in UDP-glucuronosyltransferases and 
predisposition to the development of CP is described in chapter 4. Chapter 5 shows the results 
of a large multicentre study on genetic variations in UDP-glucuronosyltransferase 1A7 and 
the risk of pancreatic disease. In chapter 6, genetic polymorphism rates in paraoxonase 1 in 
CP patients and control subjects were determined. Chapter 7 shows the assessment of 
oxidative stress in CP patients and chapters 8 and 9 represents summaries of this thesis in 
English and Dutch, respectively. 
 
The main objectives of this thesis are: 
1. To investigate the association between genetic polymorphisms in biotransformation 
enzymes and the development of chronic pancreatitis. 
2. To further elucidate the role of oxidative stress in the pathogenesis of chronic 
pancreatitis. 
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ABSTRACT 
 
Background: Glutathione S-transferases (GSTs) play critical roles in providing protection 
against electrophiles and products of oxidative stress, by catalysing the formation of 
glutathione conjugates and by eliminating peroxides. Most extensively studied are four main 
families of human cytosolic GST: GSTAlpha(A), GSTMu(M), GSTPi(P) and GSTTheta(T). 
Absence of GSTM1 or GSTT1 can be attributed to absence of the GSTM1 or GSTT1 gene 
products (null genotype) in approximately 50% and 20% of the Caucasian population, 
respectively. We investigated whether polymorphisms in the GSTM1, GSTT1 and GSTP1 
genes modified the risk for chronic pancreatitis (CP). 
Methods: DNA samples were obtained from 142 adult CP patients with alcoholic (n = 79), 
hereditary (n = 21) or idiopathic (n = 42) origin. DNA from 204 healthy controls and from 57 
alcoholic controls was analysed for comparison. Patients and controls were all of Caucasian 
origin. Genetic polymorphisms in GSTs were determined by PCR, eventually followed by 
restriction-fragment-length-polymorphism analyses in all subjects. 
Results: The rates of GSTT1 and GSTP1 genotypes did not differ between CP patients and 
healthy controls. However, GSTM1 null genotypes were significantly less common in 
alcoholic CP patients (OR = 0.56, 95%CI: 0.33-0.95) as compared to healthy controls and to 
alcoholic controls (OR = 0.52, 95%CI: 0.26-1.04). Age- and sex-adjustment bolstered our 
finding (adjusted OR = 0.48, 95%CI: 0.26-0.89). 
Conclusion: The frequency of the GSTM1 null genotype is significantly lower in alcoholic 
CP patients, especially young female. This suggests that GSTM1 null alcohol users, 
particularly young female, are less susceptible to CP. 
      28 
 
 
 
INTRODUCTION 
 
Chronic pancreatitis (CP) is a progressive inflammatory disease which eventually leads to 
functional impairment of exocrine and/or endocrine function of the organ [1-3]. The causes of 
CP are multifaceted. Most cases have been attributed to alcohol abuse, in some cases 
hereditary or metabolic factors play a role, and in a substantial part of the patients the actual 
cause remains unknown. The elucidation of genes involved in hereditary forms of CP have 
shed some insight in the pathogenesis of the disorder [4]. In autosomal dominant forms of 
hereditary CP, mutations in the cationic trypsinogen gene are linked to the disease and in 
cases with idiopathic CP, mutations in pancreatic serine protease inhibitor Kazal type 1 
(SPINK1) have been detected. Although these findings may explain development of CP in 
some patients, the pathogenesis in the large majority remains unknown [2,3]. Furthermore, the 
mechanism of tissue damage in CP is still unclear. Different hypotheses have been examined, 
including oxidative stress from endogenous origin or due to exposure of xenobiotics [5]. 
Glutathione S-transferases (GSTs) contribute to the detoxification of a number of common, 
potentially harmful, chemicals. It is a highly efficient detoxification system playing a critical 
role in providing protection against electrophiles and products of oxidative stress. GSTs 
eliminate numerous toxins by catalysing the formation of glutathione conjugates and may 
eliminate peroxides and other reactive oxygen species, thereby consuming glutathione [6,7]. 
Human cytosolic/soluble GSTs can be divided into eight families: GSTAlpha(A), 
GSTKappa(K), GSTMu(M), GSTPi(P), GSTSigma(S), GSTTheta(T), GSTZeta(Z) and 
GSTOmega(O), each subdivided into more isoenzymes, the Alpha, Mu, Pi and Theta families 
have been most extensively studied [8]. In previous studies of the human gastrointestinal tract, 
cell type specific expression of GSTs of the alpha, mu, pi and theta classes in normal 
pancreatic tissue has been described [9]. GST composition within different cell types of the 
pancreas is highly variable [9,10]. Within this variation, there is a core of GSTs, subunits P1, 
A2 and M3 make up the bulk of GST content of the pancreas [10]. 
In humans, genetic polymorphisms have been described in GSTM1, GSTT1 and GSTP1 [11]. 
Three different polymorphisms have been described at the GSTM1 locus on chromosome 
1p13.3. The most important polymorphism encodes for a partial gene deletion in GSTM1 
(GSTM1 null genotype) resulting in complete absence of GSTM1 enzyme activity. The two 
other polymorphisms do not lead to functional differences [12]. The frequency of the GSTM1 
null genotype ranges from 23 to 62% in different populations over the world and is 
approximately 50% in Caucasians [13].  
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At the GSTT1 locus on chromosome 12q11.2 one polymorphism has been described. The 
GSTT1 null genotype represents a partial gene deletion, and is associated with absence of 
functional activity of the GSTT1 enzyme [14]. The frequency of the GSTT1 null genotype 
ranges from 16 to 64% in different populations over the world, being approximately 20% in 
Caucasians [13].  
Finally, at least four different polymorphisms have been described at the GSTP1 locus on 
chromosome 11, encoding for the respective GSTPIleu105 (1a), Val105 (1b), 1c and 1d 
forms. The 1c and 1d forms are very rare but the GSTPVal105 is more common. The GSTP1 
Val105 polymorphism may result in a reduced activity of the enzyme compared to the wild 
type form (Ileu105), dependent on the electrophilic structure of the substrate [8,15-17]. Many 
studies have assessed the risk of different types of cancer in relation to the GSTM1, GSTT1 
and GSTP1 polymorphisms with inconsistent results [8,18-20]. 
We hypothesised that unknown toxins, either of endogenous or exogenous origin, could be 
involved as causative agents for CP. Since GSTs are involved in detoxification of many 
toxins, genetic variations in enzymes metabolising such molecules could modify the risk for 
CP. Therefore we investigated the possible association between CP and genetic 
polymorphisms in GSTM1, GSTT1 and GSTP1, in cohorts of non-selected adult Caucasian 
patients with CP and alcoholic and non-alcoholic Caucasian controls. 
 
METHODS 
 
Subjects 
All subjects studied were of Dutch extraction. The CP group consisted of 142 adult patients 
(80 males, 62 females). Clinical diagnosis of CP was based on one or more of the following: 
presence of a typical history (recurrent upper abdominal pain, radiating to the back, relieved 
by leaning forward or sitting upright and increased after eating), suggestive radiological 
findings, such as pancreatic calcifications or pseudocysts, and pathological findings 
(pancreatic ductal irregularities and dilatations) revealed by endoscopic retrograde 
pancreaticography or magnetic resonance imaging of the pancreas before and after stimulation 
with secretin. Twenty-one patients (15%) had a family history of CP. Diagnosis of familial 
pancreatitis (HCP) was made on the basis of two first degree relatives or three or more second 
degree relatives in two or more generations with recurrent acute pancreatitis and/or chronic 
pancreatitis for which there were no precipitating factors. Seventy-nine patients (56%) had 
alcohol induced CP (ACP). ACP was diagnosed in patients with chronic pancreatitis and an 
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alcohol consumption of 60 g (females) or 80 g (males) per day for more than two years. 
Forty-two patients (30%) were classified as having idiopathic disease (ICP), because 
precipitating factors such as alcohol abuse, trauma, medication, infection, metabolic disorders 
or positive family history were absent.  
For comparison, we discerned two control groups: a group consisting of 204 adult healthy 
subjects (76 males, 128 females) and a group of 57 alcoholic subjects (42 males, 15 females). 
We defined alcoholics, when subjects had consumed in excess of 60 g (females) or 80 g 
(males) of ethanol per day for more than two years. None of these alcoholics had CP or other 
known end-organ disease because of alcoholism. All alcoholics were treated in a 
detoxification unit because of their addiction. Informed consent was obtained from all 
controls and patients. The study was approved by the local medical ethical review committee. 
 
Blood 
For DNA extraction, blood samples were collected into EDTA tubes and stored at –20°C until 
use. DNA was isolated from whole blood using the Pure Gene DNA isolation kit, diluted to 
50 milligram per millilitre and stored at 4°C, according to the instructions from the 
manufacturer (Gentra Systems, Minneapolis, Minnesota, USA). 
 
Genotyping 
From all study objects, genetic polymorphisms in GSTM1, GSTT1 and GSTP1 were 
determined simultaneously. When an individual is null for both GSTM1 and GSTT1, there is 
always a positive control in the form of the GSTP1 PCR gene product.  
The genotyping for the polymorphisms were carried out by Polymerase Chain Reaction 
(PCR) amplification. Each PCR was carried out in a final volume of 50 μl which contained 
200 ng of genomic DNA, 10 mM Tris/HCl (pH 9.0), 50 mM KCl, 0.1% Triton X-100, 2 mM 
MgCl2, 0.25 mM dNTP’s, 100 ng of each primer and 3.0 units of Taq polymerase (Perkin 
Elmer Corp). Primers flanking the coding region of the concerning genes were designed 
according to the nucleotide sequence (Table 2.1). Genomic DNA was denaturated at 94°C for 
5 min. Thirty-five cycles were carried out, each comprising denaturation for 1 min at 94°C, 
annealing for 1 min at 58°C for GSTM1 and GSTT1 and for 1 min at 52°C for GSTP1, and 
extension for 1 min at 72°C. A final elongation step at 72°C for 5 min concludes the PCRs. 
PCR amplification was followed by agarose gel electrophoresis of the PCR products on 1.5 % 
(w/v) agarose gels (Hispanagar) run in 1.0 x TAE-buffer and stained with 0.5 μg/ml ethidium 
bromide. An amplified 650 bp fragment was observed in GSTM1(+) samples and was absent 
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in GSTM1(-) samples. For GSTT1, a 480 bp fragment was observed in GSTT1(+) samples, 
which was absent in GSTT1(-) samples. For GSTP1, aliquots (10 to 15 μl) of the PCR 
mixture were directly digested for one hour at 37°C with 10 units of the restriction enzyme 
Alw26I, followed by electrophoresis on ethidium bromide containing 2.5% agarose gels and 
photographed. We only determined the polymorphism in codon 105, being either Ileu105 or 
Val105, and are unable to discriminate between GSTP1a and 1d or GSTP1b and 1c. 
 
Table 2.1. Sequences of oligonucleotide primers used for PCR amplification 
GSTM1[26] 
   Forward:   5’-CTC CTG ATT ATG ACA GAA GCC-3’ 
   Reverse:    5’-CTG GAT TGT AGC AGA TCA TGC-3’ 
GSTT1[14] 
   Forward:   5’-TCC CTT ACT GGT CCT CAC ATC TC-3’ 
   Reverse:    5’-TCA CCG GAT CAT GGC CAG CA-3’ 
GSTP1[27] 
   Forward:   5’-GTA GTT TGC CCA AGG TCA AG-3’ 
   Reverse:    5’-AGC CAC CTG AGG GGT AAG-3’ 
 
 
Statistical analysis 
Data were analysed by SAS version 8.0. We used Chi-square statistics to estimate differences 
in the baseline characteristics in patients and controls, and differences in the presence of 
polymorphisms in GSTP1 among the different study groups. For the polymorphisms in 
GSTM1 and GSTT1, odds ratios (OR) with 95% confidence interval (95%CI) were calculated 
by logistic regression analysis. Odds ratio in a case-control study is defined as the ratio of the 
odds that the cases were exposed to the odds that the controls were exposed [21]. The cases 
are the CP patients and the exposure is the polymorphism encoding for gene deletion (null 
genotype). We compared the genotypes of alcohol induced CP patients to that of patients with 
alcoholism without CP in order to control for alcoholism. Finally, a multiple logistic 
regression analysis was performed in this subgroup of patients with ACP to study the 
association between GSTM1 polymorphism and the variables age and gender.  
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RESULTS 
 
Characteristics of patients and controls 
Age distributions were dissimilar in patients and controls, since 40% of all patients older than 
50 were ACP patients as were only 5% HCP patients (P < 0.001; Table 2.2). There was a 
difference in gender between the HCP patients, ICP patients, healthy controls and the ACP 
patients and alcoholic controls, with comparative more male subjects in the latter two groups 
(P < 0.001; Table 2.2). 
 
Table 2.2. Main characteristics of chronic pancreatitis patients and controls 
 
Characteristics 
ACP patients      HCP patients      ICP patients       All patients      Controls          Alc. Controls 
 
n  
 
Gender 
        Male 
        Female 
 
Age 
        < 40 
        40 – 50 
        > 50 
 
79                         21                         42                        142                    204                   57 
 
 
54 (68%)              8 (38%)                18 (43%)             80 (56%)           76 (37%)          42 (72%) 
25 (32%)              13 (62%)              24 (57%)             62 (44%)           128 (63%)        15 (28%) 
 
 
15 (19%)              15 (71%)              14 (33%)             44 (31%)           140 (69%)        20 (35%) 
25 (32%)              1 (5%)                  10 (24%)             36 (25%)           38 (19%)          24 (42%) 
39 (49%)              5 (24%)                18 (43%)             62 (44%)           26 (13%)          10 (18%) 
ACP: Alcoholic Chronic Pancreatitis; HCP: Hereditary Chronic Pancreatitis; ICP: Idiopathic 
Chronic Pancreatitis; Alc. Controls: Alcoholic Controls. 
 
GSTM1 genotyping 
The frequency of the GSTM1 homozygous null genotype did not differ when comparing all 
patients with CP versus normal healthy controls (Table 2.3). However, there was a significant 
under-representation of the null genotype in alcoholic CP patients (OR = 0.56, 95%CI: 0.33-
0.95). When we compared these individuals with an alcoholic control group, in order to 
control for alcoholism, a different distribution of the GSTM1 null genotype continue to exist 
(OR = 0.52, 95%CI: 0.26-1.04). There was no difference in distribution of GSTM1 genotypes 
among alcoholic and the other healthy control group (P = 0.83). For estimating all the ORs we 
used the healthy control group.  
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To study the association between GSTM1 polymorphism and variables as age and gender, we 
split up these characteristics for ACP patients and controls with regard to the GSTM1 
polymorphism (Table 2.4). The under-representation of the null genotype seems to be more 
obvious in female ACP patients (OR = 0.42, 95%CI: 0.17-1.06) as compared with male ACP 
patients (OR = 0.67, 95%CI: 0.33-1.36). When taking age into account, we saw the under-
representation of the null genotype most evidently in ACP patients younger than 40-years-of-
age (OR = 0.38, 95%CI: 0.11-1.26) and in the category 40-50 years old (OR = 0.37, 95%CI: 
0.13-1.04). After adjustment for age and gender, the association between GSTM1 and 
alcoholic CP became even more distinct, as can be seen by comparing the age-adjusted and 
gender-adjusted odds ratio (OR = 0.48, 95%CI: 0.26-0.89). There was no statistical difference 
in the frequency of the GSTM1 homozygous null genotype among HCP patients, ICP patients 
and healthy controls (Table 2.3). 
 
Table 2.3. Distribution of GSTM1, GSTT1 and GSTP1 genotypes 
 
Genes 
ACP patients         HCP patients         ICP patients         All patients          Controls 
(n=79)                     (n=21)                     (n=42)                    (n=142)                 (n=204) 
 
GSTM1 
             Present 
             Null 
             OR (95%CI) 
 
GSTT1 
             Present 
             Null 
              OR (95%CI) 
 
GSTP1 
             Ileu105/Ileu105 
             Ileu105/Val105 
             Val105/Val105 
             P-value* 
 
 
50 (63%)                 10 (48%)                 21 (50%)                82 (58%)               100 (49%) 
29 (37%)                 11 (52%)                 21 (50%)                60 (42%)               104 (51%) 
0.56 (0.33-0.95)      1.06 (0.43-2.60)      0.96 (0.49-1.87)     0.72 (0.47-1.11) 
 
 
65 (82%)                 16 (76%)                 34 (81%)                115 (81%)             167 (82%) 
14 (18%)                 5 (24%)                   8 (19%)                  27 (19%)               37 (18%) 
0.97 (0.49-1.92)      1.41 (0.49-4.09)      1.06 (0.45-2.48)     1.06 (0.61-1.84) 
 
 
42 (53%)                 8 (39%)                   22 (52%)                72 (51%)               90 (44%) 
28 (35%)                 12 (57%)                 14 (33%)                54 (38%)               90 (44%) 
9 (11%)                   1 (5%)                     6 (14%)                  16 (11%)               24 (12%) 
0.36                         0.42                         0.43                        0.46 
ACP: Alcoholic Chronic Pancreatitis; HCP: Hereditary Chronic Pancreatitis; ICP: Idiopathic 
Chronic Pancreatitis; OR: Odds Ratio; 95%CI: 95% Confidence Interval; *P-values given as 
compared to healthy control group. 
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Table 2.4. Patient characteristics versus GSTM1 genotype 
 
 
ACP patients                Controls 
(n=79)                            (n=204)  
Gender: 
 
    Male  
         GSTM1 null 
         GSTM1 present 
         OR (95%CI) 
 
    Female  
         GSTM1 null 
         GSTM1 present 
         OR (95%CI) 
 
 
 
 
21 (27%)                        37 (18%) 
33 (42%)                        39 (19%) 
0.67 (0.33-1.36) 
 
 
8 (10%)                          67 (33%) 
17 (22%)                        61 (30%) 
0.42 (0.17-1.06) 
 
Age: 
 
    < 40 years 
         GSTM1 null 
         GSTM1 present 
         OR (95%CI) 
 
     40-50 years 
         GSTM1 null 
         GSTM1 present 
         OR (95%CI) 
 
      >50 years 
         GSTM1 null 
         GSTM1 present 
         OR (95%CI) 
 
 
4 (5%)                            68 (33%) 
11 (14%)                        72 (35%) 
0.38 (0.11-1.26) 
 
 
9 (11%)                          23 (11%) 
16 (20%)                        15 (7%) 
0.37 (0.13-1.04) 
 
 
 
16 (20%)                        13 (6%) 
23 (29%)                        13 (6%) 
0.67 (0.25-1.89) 
ACP: Alcoholic Chronic Pancreatitis; OR: Odds Ratio; 95%CI: 95% Confidence Interval. 
 
GSTT1 genotyping 
There was no statistical difference observed in the distribution of GSTT1 genotypes in the 
control group as compared with the subgroups of CP or all patients (Table 2.3). Eighteen 
percent of the healthy controls were homozygous for the GSTT1 null genotype, compared to 
18% of ACP patients (OR = 0.97, 95%CI: 0.49-1.92), 24% of HCP patients (OR = 1.41, 
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95%CI: 0.49-4.09), 19% of ICP patients (OR = 1.06, 95%CI: 0.45-2.48) and 19% of all 
patients (OR = 1.06, 95%CI: 0.61-1.84).  
 
GSTP1 genotyping 
There were no statistical differences between the homozygous Ileu105 genotype, homozygous 
Val105 genotype and heterozygotes among the ACP (P = 0.36), HCP (P = 0.42), ICP (P = 
0.43) or all patients (P = 0.46) and the healthy control subjects (Table 2.3). The genotype 
distribution of all groups studied was as expected according to the Hardy-Weinberg 
equilibrium. There was also a lack of differences in GSTP1 allele (*Ileu105 and *Val105) 
frequencies between HCP patients (0.78 *Ileu105, 0.22 *Val105), ACP patients (0.62 
*Ileu105, 0.38 * Val105), ICP patients (0.61 *Ileu105, 0.39 *Val105) and healthy (0.66 
*Ileu105, 0.34 *Val105) or alcoholic controls (0.65 *Ileu105. 0.34 *Val105). 
 
We have also examined the following combinations of polymorphisms in GSTM1, GSTT1 
and GSTP1 among CP patients and control subjects. GSTM1 null and GSTT1 null (n = 38, P 
= 0.37), GSTM1 null and GSTPIleu105/Val105 (n = 72, P = 0.15), GSTM1 null and 
GSTPVal105/Val105 (n = 22, P = 0.78), GSTT1 null and GSTPIleu105/Val105 (n = 28, P = 
0.66), GSTT1 null and GSTPVal105/Val105 (n = 11, P = 0.89), GSTM1 null, GSTT1 null 
and GSTPIleu105/Val105 (n = 14, P = 0.23) and finally, GSTM1 null, GSTT1 null and 
GSTPVal105/Val105 (n = 3, P = 0.58). The distribution of none of these combinations of 
polymorphisms were statistical different between the various study groups 
 
DISCUSSION 
 
We found that GSTM1 null genotypes were significantly less common in ACP patients as 
compared to HCP patients, ICP patients and healthy controls. This suggests that individuals 
bearing the GSTM1 null genotype may be better protected against CP induced by alcohol or 
its metabolites. After splitting up the ACP patients for age and sex, we noticed that the 
GSTM1 null genotype was chiefly less common in female ACP patients, younger than 50 
years. However, one should be aware of the limitations of dividing groups into smaller 
subgroups, because of lack of power to detect statistical differences.  
A different distribution of the GSTM1 polymorphism continues to exist, when we compared 
the alcoholic CP patients with an alcoholic control group. With this study, we only controlled 
for alcohol consumption, since the information about smoking, dietary habits, medication, etc. 
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from our study population is not available. In prospective studies we recommend to control 
for the other possible confounding factors as well.  
To our best knowledge, GSTM1 is not involved in alcohol metabolism, which suggests that 
an indirect mechanism must be responsible for the protection against ACP in the GSTM1 null 
individuals. Three possible explanations are: at first; biotransformation by GSTM1 can, in a 
minority of the reactions, result in bioactivation of certain molecules instead of detoxification. 
A small number of GST substrates yields a GSH conjugate, or a metabolite of the conjugate, 
that is more reactive than the parental compound. Moreover, GSH conjugates are relatively 
unstable and the reaction product is either cleaved to liberate an unconjugated metabolite that 
requires further detoxification, or the reaction is reversible allowing regeneration of the 
original compound. It might be possible that reactive intermediates or toxic metabolites 
generated by GSTM1 may initiate or promote the development of ACP.  
Secondly; although the majority of GST substrates are, either xenobiotics or products of 
oxidative stress, a small number of endogenous compounds are also metabolized by GST. 
Leukotriene A4 and prostaglandin H2 are metabolized by GST as part of their normal 
biosynthetic pathways [11]. Since CP is a progressive inflammatory disease, the absence of 
enzyme activity of GSTM1 might be protective because the formation of inflammatory 
mediators as leukotriene A4 and prostaglandin H2 could be inhibited.  
At third; in a recent paper by London et al. [22], it was shown that individuals consuming 
cruciferous vegetables and bearing the GSTM1 null genotype were better protected against 
lung cancer. They suggest that a possible explanation could be the protecting effect of 
isothiocyanates. The actual protective metabolites formed after digestion of cruciferous 
vegetables is higher in GSTM1 null individuals, since the isothiocyanates are metabolised by 
GSTM1. A similar indirect mechanism could be operational for patients at risk for CP.  
Our findings differ from those of Bartsch et al [23], in which the prevalence of GSTM1 null 
genotypes did not differ in subjects with alcoholic and non-alcoholic CP versus controls. 
Nevertheless, when they combined all pancreatic disease cases, which were alcoholic CP, 
non-alcoholic CP and pancreatic cancer cases, they find a significant under-representation of 
the GSTM1 null genotype in all pancreatic disease cases. Also in cancer research, there have 
been conflicting reports with regard to susceptibility to a particular type of cancer and genetic 
polymorphisms in GSTs and other biotransformation enzymes [20,24]. 
We did find no differences in the rates of GSTT1 and GSTP1 genotypes between CP patients 
and healthy controls, but no other comparable studies have been performed so far. Increased 
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expression of GSTP1 was shown recently in the islets of chronic pancreatitis specimens, as 
compared with tissue from the normal pancreas or secondary pancreatitis [5,25].  
In conclusion, the present study suggests an association between the null polymorphism of the 
GSTM1 gene and the predisposition to develop alcohol-induced pancreatitis. In fact our 
results might suggest that the presence of the GSTM1 null genotype provide protection 
against CP in alcohol users, particularly female alcoholics under fifty.  
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ABSTRACT 
 
Background: Alcohol misuse is now regarded as an important risk factor for development of 
chronic pancreatitis (CP). However, not every alcohol misuser develops CP and therefore it 
might be suggested that susceptibility could be further influenced by inter-individual 
variations in the activities of alcohol-metabolising enzymes. Several genetic polymorphisms 
that may affect the activities of alcohol-metabolising enzymes have been described. Therefore 
we determined whether polymorphisms in the genes for alcohol dehydrogenase 3 (ADH3) or 
cytochrome P450 2E1 (CYP2E1) predispose to the development of CP.  
Methods: DNA samples were obtained from 142 adult CP patients with hereditary (n = 21), 
alcoholic (n = 82) or idiopathic (n = 39) CP. DNA from 128 healthy controls and from 93 
alcoholic controls was analysed for comparison. Patients and controls were all of Caucasian 
origin. Genetic polymorphisms in ADH3 and CYP2E1 were determined by PCR, followed by 
restriction-fragment-length-polymorphism analyses in all subjects.  
Results: The frequencies of ADH3 and CYP2E1 c1c2 genotypes did not differ between CP 
patients and alcoholic and healthy controls. However, a trend of a higher frequency of the 
CYP2E1 intron 6 D allele was demonstrated in patients with alcohol induced CP, compared to 
that of healthy controls (OR = 3.03, 95%CI: 1.0-9.1) and alcoholic controls (OR = 2.76, 
95%CI: 0.9-8.7).  
Conclusion: These data suggest that the presence of the CYP2E1 intron 6 DD genotype might 
confer a higher risk of alcoholic CP. 
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INTRODUCTION 
 
Chronic pancreatitis (CP) is a progressive inflammatory disease, which eventually leads to 
functional impairment of exocrine and/or endocrine function of the organ [1-3]. Alcohol 
(ethanol) is regarded as the main cause of CP, in fact alcohol misuse accounts for 70-80% of 
all cases of CP [4,5]. However, only 5-10% of heavy drinkers do develop pancreatitis [6], 
while the mechanism as to how alcohol causes CP remains unknown [7]. In addition, other 
etiological factors such as heredity, smoking, anatomical variations, and various metabolic 
disorders have been identified. However, in a substantial part of the patients there are no 
obvious risk factors and the disease in these patients is classified as idiopathic CP [8]. 
Modulating genetic factors underlying the susceptibility to CP remain elusive. Given the 
importance of alcohol consumption in the aetiopathogenesis of CP, we have focussed on 
genes involved in alcohol metabolism. Ethanol is mainly oxidised to acetaldehyde by alcohol 
dehydrogenases (ADHs). Oxidation of alcohol by the cytochrome P450 2E1 (CYP2E1) 
enzyme is important especially in chronic alcohol misusers as it is inducible up to 10-fold by 
consumption of alcohol. Several polymorphisms in the genes encoding for these enzymes may 
influence the corresponding enzyme activities and may thus affect toxicity of alcohol [9]. 
ADH enzymes are encoded by at least six gene loci (ADH1-6) [10] and polymorphisms have 
been identified in two of these genes; ADH2 and ADH3 [11]. In Caucasians however, only the 
ADH3 locus is polymorphic. Two ADH3 alleles exist; ADH3*1 and ADH3*2, encoding the 
subunits γ1 and γ2 respectively, which differ by one amino acid [12]. The γ1γ1 isoenzyme 
metabolises alcohol at 2.5-fold higher rate as compared to the γ2γ2 isoenzyme [11].  
CYP2E1, a microsomal enzyme, is also able to oxidise ethanol and particularly contributes to 
ethanol metabolism in chronic alcohol consumers. Genetic polymorphisms in CYP2E1 have 
been demonstrated in the transcription-regulation region (alleles c1 and c2) and in intron 6 
(alleles D and C) [13,14]. The presence of the c2 or C alleles was associated with enhanced 
enzyme activity [13-15]. 
In the present study we investigated the association between CP and the ADH3 and CYP2E1 
gene polymorphisms described above, in cohorts of non-selected adult Caucasian patients 
with CP and alcoholic and non-alcoholic Caucasian controls. 
 
 
 
      43
 
 
 
METHODS 
 
Subjects 
The study was approved by the local medical ethical review committee and all subjects gave 
their written informed consent. All subjects studied were Caucasians of Dutch extraction. The 
CP group consisted of 142 adult patients (80 males, 62 females). Twenty-one patients (15%) 
had a family history of CP (HCP), 82 patients (58%) had alcohol induced CP (ACP) and 39 
patients (27%) were classified as having idiopathic chronic pancreatitis (ICP).  
The clinical diagnosis of CP was based on one or more of the following criteria: (1) presence 
of typical complaints (recurrent upper abdominal pain, radiating to the back, relieved by 
leaning forward or sitting upright and increased after eating); (2) suggestive radiological 
findings, such as pancreatic calcifications or pseudocysts, and (3) pathological findings 
(pancreatic ductal irregularities and dilatations) revealed by endoscopic retrograde 
pancreaticography or magnetic resonance imaging of the pancreas before and after stimulation 
with secretin. Diagnosis of HCP was made on the basis of two first-degree relatives or three 
or more second-degree relatives in two or more generations, who suffered from recurrent 
acute pancreatitis or chronic pancreatitis for which there was no precipitating factor. ACP was 
diagnosed in patients who consumed more than 60 g (females) or 80 g (males) of ethanol per 
day for more than 2 years. Two of the 82 ACP patients also suffer from other alcohol 
associated organ damage, namely liver cirrhosis. Patients were classified as having ICP when 
precipitating factors such as alcohol misuse, trauma, medication, infection, metabolic 
disorders or a positive family history were all absent. 
For comparison, we discerned two control groups: a group consisting of 128 adult healthy 
subjects (75 males, 53 females) recruited by advertisement in a local paper, and a group of 93 
alcoholic subjects (64 males, 29 females), who were being treated in a detoxification unit 
because of their addiction. We defined alcoholics as subjects who consumed in excess of 60 g 
(females) or 80 g (males) of ethanol per day for more than 2 years. None of the alcoholics had 
CP or other known end-organ disease because of their alcoholism. 
 
Genotyping 
DNA was isolated from whole blood using the Pure Gene DNA isolation kit, and the isolation 
was performed according to the instructions from the manufacturer (Gentra systems). 
The genotyping for the polymorphism in ADH3 was carried out by polymerase chain reaction 
(PCR) amplification according to the method of Xu et al [16]. Subsequently the PCR product 
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was digested using restriction enzyme SspI (PCR/RFLP). The ADH3*1 allele contains an 
additional restriction site for SspI, yielding fragments of 63 and 67 bp, which is not present in 
the ADH3*2 allele. 
The CYP2E1 genotypes were determined by PCR/RFLP methods as described elsewhere [17]. 
The restriction enzymes RsaI and PstI were used to discern the c1 and c2 alleles of the 5'-
flanking region, while the enzyme DraI was used to detect the D and C polymorphisms in 
intron 6. 
 
Statistical analyses 
Data were analysed by SAS version 8.0. Differences in the baseline characteristics of patients 
and control groups were estimated with Fisher Exact test and t-test. Chi-square statistics was 
used to estimate differences in the presence of genetic polymorphisms in ADH3, CYP2E1 c1 
and c2 or D and C polymorphisms among the different study groups. (When one of the 
genotypes has expected counts of less than 5, Chi-squared may not be a valid test, we 
therefore used Fisher’s exact test instead in these cases.) The distribution of each 
polymorphism among the control population was tested whether it fitted the Hardy-Weinberg 
equilibrium. 
We compared the genotypes of ACP patients to those of alcoholic controls in order to correct 
for alcoholism for the D and C polymorphism in CYP2E1. Odds ratios (OR) with 95% 
confidence interval (95%CI) were calculated by logistic regression analysis. 
Because the mean age in the ACP group did not match that of the alcoholic controls, a 
multiple logistic regression analysis was performed in the group of ACP patients to study the 
association between the CYP2E1 DC polymorphism and the variable age to estimate an 
adjusted OR with 95%.  
Finally for the allele frequencies in ADH3, CYP2E1 c1 and c2 or D and C polymorphisms, 
OR with 95% confidence interval (95%CI) were calculated by logistic regression analysis. 
 
RESULTS 
 
Characteristics of patients and controls 
Characteristics of patients with CP and controls are denoted in Table 3.1. There was a 
difference in sex between the HCP or ICP patients versus the normal healthy controls, with 
comparative more female subjects in the former two groups (both P < 0.05). Age distribution 
was dissimilar in HCP patients, as these patients develop CP at a younger age than do the 
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other CP patients, explaining why this separate group was significantly younger than the 
normal control group (P < 0.05). The mean age of ACP patients was higher compared to that 
of the alcoholic control group (P < 0.05), but was not different compared to the healthy 
controls.  
There were no differences in smoking habits between patients and healthy controls or between 
ACP patients and alcoholic controls, but unfortunately the information about smoking is only 
available from a limited number of the subjects.  
 
Table 3.1. Main characteristics of patients with chronic pancreatitis and controls 
 
Characteristics 
HCP                    ACP                    ICP                    All patients          Alc. Controls        Controls 
 
n  
 
Gender 
      Male/Female 
 
Age (years) 
      Mean +/- SD 
 
Smoking 
      Yes/No 
      Unknown 
 
21                        82                        39                        142                       93                           128 
 
 
8/13*                   56/26                   16/23*                  80/62                    64/29                      75/53 
 
 
35 +/- 21*           50 +/- 9**             44 +/- 15              46 +/-14                45 +/- 14                45 +/- 11 
 
 
8/9                      65/7                     18/10                    91/23                   84/9                        32/13 
7                         10                        11                         28                         21                           83 
HCP: Hereditary Chronic Pancreatitis; ACP: Alcoholic Chronic Pancreatitis; ICP: Idiopathic 
Chronic Pancreatitis; Alc. Controls: Alcoholic Controls; * = P-values < 0.05 as compared to 
normal control group; ** = P-values < 0.05 as compared to alcoholic control group  
 
ADH3 genotyping 
There were no statistical differences in the distribution of the homozygous γ1γ1 genotype, the 
homozygous γ2γ2 genotype and the heterozygous γ1γ2 genotype among patients with HCP, 
ACP, ICP versus the healthy control subjects (Table 3.2) or ACP patients versus alcoholic 
controls (Table 3.3). The genotype distribution of all groups studied followed the Hardy-
Weinberg equilibrium. The ratio of the γ1 and γ2 allele in the different patient and control 
groups did not demonstrate any statistical difference either (Tables 3.4 and 3.5).  
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Table 3.2. Distribution of ADH3, CYP2E1 c1c2 and CYP2E1 intron 6 genotypes in patients 
with CP and healthy controls 
 
Genotype 
HCP                      ACP                      ICP                       Controls 
(n=21)                   (n=82)                   (n=39)                  (n=128)  
ADH3 
            γ1γ1   
            γ1γ2  
            γ2γ2  
           P-value * 
 
CYP2E1 c1c2 
            c1c1   
            c1c2  
            c2c2  
           P-value * 
            
CYP2E1 DC 
             DD 
             DC 
             CC 
             P-value * 
 
8 (38%)                 27 (33%)               14 (36%)             36 (28%) 
9 (43%)                 40 (49%)               18 (46%)             68 (53%) 
4 (19%)                 15 (18%)               7 (18%)               24 (19%) 
0.61                       0.75                       0.64 
 
 
21 (100%)             75 (91%)               39 (100%)           122(95%) 
0 (0%)                   7 (9%)                   0 (0%)                 6 (5%) 
0 (0%)                   0 (0%)                   0 (0%)                 0 (0%) 
0.60                       0.26                       0.34 
 
 
21 (100%)             78 (95%)               37 (95%)             112 (87%) 
0 (0%)                   4 (5%)                   2 (5%)                 14 (11%) 
0 (0%)                   0 (0%)                   0 (0%)                 2 (2%) 
0.43                       0.15                       0.63 
HCP: Hereditary Chronic Pancreatitis; ACP: Alcoholic Chronic Pancreatitis; ICP: Idiopathic 
Chronic Pancreatitis; *P-values are estimated with Chi-square or with Fisher Exact test when 
cells have expected counts less than 5. 
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Table 3.3. Distribution of ADH3, CYP2E1 c1c2 and CYP2E1 intron 6 genotypes in patients 
with alcohol induced chronic pancreatitis and alcoholic control subjects 
 
Genotype 
ACP                      Alc. Controls 
(n=82)                   (n=93)  
ADH3 
            γ1γ1   
            γ1γ2  
            γ2γ2  
           P-value * 
 
CYP2E1 c1c2 
            c1c1   
            c1c2  
            c2c2  
            P-value * 
            OR (95%CI) 
 
CYP2E1 DC 
            DD 
            DC 
            CC 
            P-value * 
            OR (95%CI) 
 
27 (33%)               26 (28%) 
40 (49%)               48 (52%) 
15 (18%)               19 (20%) 
0.79 
 
 
75 (91%)               88 (95%) 
7 (9%)                   5 (5%) 
0 (0%)                   0 (0%) 
0.41 
0.61 (0.2-2.0) 
 
 
78 (95%)               81 (87%) 
4 (5%)                   12 (13%) 
0 (0%)                   0 (0%) 
0.11 
2.89 (0.9-9.3) 
ACP: Alcoholic Chronic Pancreatitis; Alc. Controls: Alcoholic Controls; *P-values are 
estimated with Chi-square or with Fisher Exact test when cells have expected counts less than 
5. OR: Odds Ratio, OR is given for the c1c1 vs. c1c2 and the DD vs. DC genotype, 
respectively; 95%CI: 95% Confidence Interval 
 
CYP2E1 c1c2 genotyping 
There were no statistical differences in the distribution of CYP2E1 c1c2 genotype among 
groups (Table 3.2). None of the subjects investigated had the homozygous c2c2 genotype. 
Most subjects studied (95%), both patients and controls, carried the homozygous c1c1 
genotype, while the remaining 5% was heterozygous (c1c2 genotype). The distribution of 
CYP2E1 c1c2 genotype followed the Hardy-Weinberg equilibrium. The c1 and c2 allele 
frequencies showed no statistical differences between different CP patient groups and control 
subjects (Tables 3.4 and 3.5). 
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Table 3.4. Allele frequencies of ADH3, CYP2E1 c1c2 and CYP2E1 intron 6 in patients with 
CP and healthy controls 
 
Allele 
HCP                      ACP                      ICP                       Controls 
(n=42)                   (n=164)                (n=78)                   (n=256)  
ADH3 
            γ1   
            γ2  
           P-value * 
           OR (95% CI) 
 
CYP2E1 c1c2 
            c1 
            c2  
            P-value * 
            OR (95% CI) 
            
CYP2E1 DC 
             D 
             C 
             P-value* 
            OR (95% CI) 
 
 
0.60                       0.57                       0.59                      0.55 
0.40                       0.43                       0.41                      0.45 
0.67                       0.66                       0.59 
1.22 (0.6-2.4)        1.11 (0.8-1.7)        1.19 (0.7-2.0) 
 
 
1.00                       0.96                       1.0                        0.98 
0.0                         0.04                       0.0                        0.02 
0.68                       0.41                       0.38 
-                             0.54 (0.2-1.6)        - 
 
 
1.0                         0.98                       0.97                      0.93 
0.0                         0.02                       0.03                      0.07 
0.15                       0.07                       0.24 
-                             3.03 (1.0-9.1)       2.87 (0.7-12.7) 
HCP: Hereditary Chronic Pancreatitis; ACP: Alcoholic Chronic Pancreatitis; ICP: Idiopathic 
Chronic Pancreatitis; OR: Odds Ratio; 95%CI: 95% Confidence Interval 
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Table 3.5. Allele frequencies of ADH3, CYP2E1 c1c2 and CYP2E1 intron 6 in patients with 
alcohol induced chronic pancreatitis and alcoholic control subjects 
 
Allele 
ACP                      Alc. Controls 
(n=164)                 (n=186)  
ADH3 
            γ1   
            γ2  
           P-value * 
            OR (95%CI) 
 
CYP2E1 c1c2 
            c1 
            c2  
           P-value*  
            OR (95%CI) 
 
CYP2E1 DC 
            D 
            C 
            P-value * 
           OR (95%CI) 
 
0.57                       0.54 
0.43                       0.46 
0.57 
1.15 (0.7-1.8) 
 
 
0.96                       0.97 
0.04                       0.03 
0.60 
0.62 (0.2-2.0) 
 
 
0.98                       0.94 
0.02                       0.06 
0.12 
2.76 (0.9-8.7) 
ACP: Alcoholic Chronic Pancreatitis; Alc. Controls: Alcoholic Controls; OR: Odds Ratio; 
95%CI: 95% Confidence Interval 
 
CYP2E1 DC genotyping: 
There were no significant statistical differences in the distribution of the CYP2E1 DC 
genotype between HCP patients, ACP patients, ICP patients and healthy controls (Table 3.2). 
However, a slight tendency of a higher frequency of the CYP2E1 DD genotype was detected. 
The distribution of CYP2E1 DC genotype followed the Hardy-Weinberg equilibrium. 
Comparison of the ACP patients with the alcoholic control group in order to control for 
alcoholism, demonstrated a similar tendency of a higher frequency of the CYP2E1 DD 
genotype in the former group, however significance was not reached (P = 0.11; OR = 2.89, 
95%CI: 0.9-9.3, Table 3.3). As the mean age of ACP patients was higher compared with that 
of alcoholic controls, we controlled for this confounding factor. We estimated an adjusted OR 
for age, which showed the same tendency of a higher frequency of the CYP2E1 DD genotype 
in the ACP patient group (adjusted OR = 2.31, 95%CI: 0.7-7.7). 
The ratio of allele frequencies showed, in accordance with the genotype distribution of 
CYP2E1 DC, a trend of a higher frequency of the CYP2E1 D allele between ACP patients and 
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healthy controls (P = 0.07; OR = 3.03, 95%CI: 1.0-9.1, Table 3.4). Comparison of the allele 
frequencies in ACP patients with that of alcoholic control subjects, demonstrated a similar 
tendency of a higher frequency of the D allele in the ACP patient group, but here again 
significance was not reached (P = 0.12; OR = 2.76, 95%CI: 0.9-8.7, Table 3.5). 
 
DISCUSSION 
 
In this study, frequencies of genetic polymorphisms in ADH3 or in the transcription-
regulation region of CYP2E1 (c1c2) in control groups were similar to those in CP patients of 
various aetiologies. However, we detected a trend of a higher frequency of the CYP2E1 intron 
6 D allele in patients with alcohol induced CP as compared to that of healthy controls (OR = 
3.03, 95%CI: 1.0-9.1) and alcoholic controls (OR = 2.76, 95%CI: 0.9-8.7). This suggests a 
weak positive association between the homozygous CYP2E1 DD genotype in Caucasians and 
the development of ACP. 
The CYP2E1 DD genotype, which may be associated with a less efficient microsomal 
alcohol-metabolising enzyme that may either delay the formation of acetaldehyde, the highly 
toxic metabolite of alcohol, and so permits higher intake of alcohol, or may result in a higher 
pressure on the cytosolic ADH oxidising system in patients with CP. It is possible that a shift 
from microsomal to cytosolic oxidation of alcohol might generate more damage to vital 
cellular systems.  
So far only a few studies have focussed on the association between various genotypes of 
alcohol-metabolising enzymes and susceptibility to pancreatitis in Caucasians. In their review, 
Haber et al. [18] argued that the genotypes of ADH3 were not significantly associated with the 
development of alcoholic pancreatitis. In contrast, some studies reported a positive association 
between the ADH3*1 allele and alcohol induced CP [19,20]. In more recent studies, 
polymorphisms in both ADH3 and CYP2E1 did not affect the risk of CP [21,22]. Also 
Klingenberg et al. [23] did not find an association between ADH3 polymorphisms and alcohol 
associated pancreatitis. However, there appears to be an association between ADH genotypes 
with less active alcohol-metabolising enzymes and alcoholic liver cirrhosis [22], whereas 
Grove et al. [21] reported that the c2 allele of CYP2E1, possibly resulting in enhanced enzyme 
activity, was associated with a higher risk of alcoholic liver disease. In similar studies with 
Japanese CP patients and controls, no associations between variant ADH3 or CYP2E1 
genotypes and CP were found [23,24]. However, a positive association between alcoholic CP 
and the ADH2(2) allele in the Japanese population was detected [23,24].  
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The relative importance of the ADH3 and CYP2E1 enzyme activities to overall ethanol 
metabolism is unknown, although CYP2E1 by virtue of its inducibility by chronic intake of 
ethanol, is probably important in chronic alcohol misusers only [11,25]. Other enzymes 
involved in the metabolism of ethanol, are enzymes of the aldehyde dehydrogenase (ALDH) 
family and the other members of the ADH family. In this study, genotype patterns of ADH2 
and ALDH2 were not examined, because the relative common genetic polymorphisms in 
ADH2*2 and ALDH2*2 as often described in Japanese individuals [23,24] are very rare in 
Caucasians. 
Because of the low frequency of the CYP2E1 C allele, we are unable to define which CP 
subtype is most associated with the CYP2E1 D allele. However, when comparing the 
alcoholic CP patients with the alcoholic control group without CP, in order to correct for 
alcohol misuse, a trend for the positive association between CP and the CYP2E1 DD genotype 
was still present. 
Our finding has to be viewed in perspective of potential limitations. First, we are lacking 
information on the nature of the alcoholic beverages consumed, and it might be argued that 
differences reported here are caused by differences in the types of alcoholic consumption. 
This seems unlikely, since ACP patients and alcoholic controls stem from a cultural 
homogeneous population. Second, we do not have precise data on potential confounding 
factors for the alcoholic and healthy controls, such as dietary habits, and use of medication or 
drugs. Third, the most important confounding factor, smoking, was not fully investigated. 
Although data on smoking habits were not available for every subject, our data suggest that 
smoking was similar among groups and did not influence the results from this study. In 
conclusion, our data suggest that the risk of ACP might to be associated with a genetic 
polymorphism in intron 6 of CYP2E1, whereas associations with other polymorphisms in 
ADH3 and CYP2E1 are lacking. This result might point to a higher risk for ACP in 
individuals with chronic alcohol consumption and a slow microsomal ethanol oxidising 
genotype. 
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ABSTRACT 
 
Background: Chronic pancreatitis (CP) is associated with alcohol abuse, smoking and other 
dietary or environmental factors. UDP-glucuronosyltransferases (UGTs) are phase II 
detoxifying enzymes responsible for glucuronidation of various exogenous and endogenous 
compounds. Genetic variations, resulting in variable rates of glucuronidation, are of 
toxicological and physiological importance and are frequently associated with diseases. 
Recently, a genetic polymorphism in UGT1A7 was possibly associated with an increased risk 
for chronic pancreatitis. We investigated whether polymorphisms in the genes for UGT1A1, 
UGT1A6 and UGT1A8 modified the risk for chronic pancreatitis. 
Methods: DNA samples were obtained from 258 adult CP patients with alcoholic (n = 153), 
hereditary (n = 25) or idiopathic (n = 80) origin. DNA from 140 healthy controls was 
analysed for comparison. Patients and controls were all of Caucasian origin. Genetic 
polymorphisms in UGTs were determined by PCR, eventually followed by restriction-
fragment-length-polymorphism analyses in all subjects. 
Results: The distribution of the various alleles of UGT1A1, UGT1A6 and UGT1A8 did not 
differ between CP patients and healthy controls.  
Conclusion: These data suggest that genetic polymorphisms in UGT1A1, UGT1A6 and in 
UGT1A8 do not predispose to the development of CP in Caucasians.  
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INTRODUCTION 
 
Chronic pancreatitis (CP) is a progressive inflammatory disease, which eventually leads to 
functional impairment of exocrine and/or endocrine function of the organ [1-4]. The causes of 
CP are multifaceted. Most cases have been attributed to alcohol abuse, but other etiological 
factors such as heredity, smoking, anatomical variations, and various metabolic disorders 
have also been identified [5]. 
The elucidation of genes involved in hereditary forms of CP has shed some insight in the 
pathogenesis of the disorder [6]. In autosomal dominant forms of hereditary CP, mutations in 
the cationic trypsinogen gene are linked to the disease, whereas in cases with idiopathic CP, 
mutations in pancreatic serine protease inhibitor Kazal type 1 (SPINK1) have been detected. 
Although these findings may explain development of CP in some patients, the pathogenesis in 
the majority of cases remains unknown, and it is likely that there are additional genetic factors 
modifying the susceptibility towards CP [1,3]. 
The mechanism of tissue damage in CP is unclear. Various toxins have been implied as a 
possible cause, including oxidative stress from endogenous origin or chemical stress by 
environmental or lifestyle related xenobiotics [7]. 
UDP-glucuronosyltransferases (UGTs), a family of biotransformation enzymes located in the 
endoplasmic reticulum of many cell types, contribute to the detoxification of a number of 
common, potentially harmful chemicals, by catalysing the addition of the glucuronyl group 
from UDP-glucuronic acid, to a wide variety of endogenous or exogenous compounds [8]. 
The resulting metabolites in general are less biologically active and possess increased water 
solubility, enhancing their biliary or renal excretion. Beside detoxification however, 
biotransformation reactions catalysed by UGT enzymes in a minority of cases, can result in 
bioactivation of molecules. Reactive intermediates and toxic metabolites can be liberated with 
detrimental consequences [9-11]. 
UGT enzymes have been classified on the basis of sequence homology into the UGT1A, 
UGT2A and 2B subfamilies [12]. Family 1A isoforms are derived from a single gene locus on 
chromosome 2q37 [13]. In humans the UGT1A is composed of at least nine functional 
proteins (UGT1A1, UGT1A3-UGT1A10), encoded by five exons. Exons 2 to 5 are shared by 
all UGT1A genes, whereas exon 1 is different and determines the specific properties of the 
UGT1A members [12]. Family 2 enzymes include UGT2A1, 2B4, 2B7, 2B10, 2B11, 2B15 
and 2B17, encoded by separate genes, mapped on chromosome 4 [14]. Most human UGT 
isoforms are expressed in the liver, but high UGT expression levels have also been reported 
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extrahepatically, indicating that other organs also play a major role in glucuronidation [15-
17]. 
Recently, functional polymorphisms in the genes encoding the various UGT1 family members 
have been discovered [18-21]. UGT1A1 has been most extensively studied due to its 
importance in clearing bilirubin. So far over 100 different substrates have been identified, 
including endogenous estrogens and numerous xenobiotic compounds, such as phenols and 
flavonoids [22-24]. A genetic polymorphism in the promotor region of UGT1A1, which 
contains an extra TA repeat (TA)7TAA instead of (TA)6TAA, results in reduced gene 
expression with concomitant reduction in enzyme activity [25-27]. This so-called TATA box 
mutation (UGT1A1*28) in Caucasians may lead to hyperbilirubinemia and is associated with 
Gilbert's syndrome [28,29].  
UGT1A6 has the capacity to glucuronidate many xenobiotic phenols and genetic defects may 
lead to lower rates of metabolism of a number of phenols [30]. Two missense mutations on 
the same allele of UGT1A6 (UGT1A6*2) result in T181A and R184S amino acid substitutions 
with reduced enzyme activity [30,31]. In most cases both mutations are linked, although the 
single R184S mutation has been identified incidentally. The presence of an UGT1A6*2 allele 
may reduce the protective effect of aspirin against colon adenomas [32]. 
UGT1A8 in the gastrointestinal tract is expressed exclusively extrahepatic, and might play an 
important role in first pass metabolism [18]. The UGT1A8 enzyme participates in the 
metabolism of drugs, dietary and environmental carcinogens in addition to endogenous 
substrates [33]. Recently, three allelic variants of the UGT1A8 have been identified: 
UGT1A8*1, UGT1A8*2 and UGT1A8*3, resulting from two amino acid substitutions at 
positions 173 and 277. Both UGT1A8*1 and UGT1A8*2 gene products have similar catalytic 
properties, whereas presence of the UGT1A8*3 allele leads to dramatically reduced activity 
towards substrates [20]. 
Recently, genetic polymorphisms in another extrahepatic member of the UGT family 
(UGT1A7) was possibly linked to an increased risk for chronic pancreatitis and pancreatic 
cancer [34]. We therefore hypothesised that toxins, either of endogenous or exogenous origin 
and potential substrates for UGT1A1, 1A6 or 1A8, could be also involved as causative agents 
for CP. Since genetic variations in enzymes metabolising such molecules could also modify 
the risk for CP, we investigated the possible association between CP and genetic 
polymorphisms in UGT1A1, UGT1A6 and UGT1A8, in a cohort of non-selected Caucasian CP 
patients. 
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METHODS 
 
Subjects 
The study was approved by the local medical ethical review committee and all subjects gave 
their written informed consent. All subjects studied were Caucasians of Dutch (50%) and 
Hungarian (50%) extraction. The CP patients group consisted of 258 adult patients (164 
males, 94 females). Twenty-five patients (10%) had a family history of CP (HCP), 153 
patients (59%) had alcohol induced CP (ACP) and 80 patients (31%) were classified as 
having idiopathic chronic pancreatitis (ICP).  
The clinical diagnosis of CP was based on one or more of the following criteria: presence of 
typical complaints (recurrent upper abdominal pain, radiating to the back, relieved by leaning 
forward or sitting upright and increased after eating); suggestive radiological findings, such as 
pancreatic calcifications or pseudocysts, and pathological findings (pancreatic ductal 
irregularities and dilatations) revealed by endoscopic retrograde pancreaticography or 
magnetic resonance imaging of the pancreas before and after stimulation with secretin. HCP 
was diagnosed on the basis of two first-degree relatives or three or more second-degree 
relatives in two or more generations, which suffered from recurrent acute pancreatitis or 
chronic pancreatitis for which there was no precipitating factor. ACP was diagnosed in 
patients who consumed more than 60 g (females) or 80 g (males) of ethanol per day for more 
than two years. Four of the 153 ACP patients also suffer from liver cirrhosis. Patients were 
classified as having ICP when precipitating factors such as alcohol abuse, trauma, medication, 
infection, metabolic disorders and/or a positive family history were all absent. 
For comparison, we collected a control group consisting of 140 adult healthy subjects (53 
males, 87 females) recruited by advertisement in a local paper. 
 
Blood 
For DNA extraction, blood samples were collected into EDTA tubes and stored at –20°C until 
use. DNA was isolated from whole blood using the Pure Gene DNA isolation kit according to 
the instructions from the manufacturer (Gentra Systems, Minneapolis, Minnesota, USA), 
diluted to 50 milligram per millilitre and stored at 4°C. 
 
Genotyping 
In the UGT1A1 gene, the number of TA-repeats in the promotor region was analysed using 
the polymerase chain reaction conditions and primers (C and D) as described before [26]. 
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Amplification was confirmed by agarose electrophoresis before fragments were resolved on 
13% polyacrylamide gels (19:1 acrylamide/bisacrylamide; Biorad) in Tris-Borate EDTA 
buffer as described before [35]. Gels (20x20x0.075cm) were run at 400 V for 4 h and stained 
with ethidium bromide for 15 min. Fragments of 98 bp indicate for the UGT1A1*1 allele, 
containing 6 TA repeats, and fragments of 100 bp indicate for the UGT1A1*28 allele, 
containing 7 TA repeats. 
The T181A and R184S polymorphisms in exon 1 of the UGT1A6 gene were studied using 
polymerase chain reaction amplification according to the method recently described [36]. 
Subsequently the PCR product was digested using restriction enzymes NsiI for the T181A 
substitution and Fnu4HI for the R184S substitution. Digested samples were run on a 3% 
agarose gel and stained with ethidium bromide. The UGT1A6*2 allele contains an additional 
restriction site for both restriction enzymes used here, which is not present in the UGT1A6*1 
allele. 
Both polymorphisms in the UGT1A8 gene corresponding with amino acid substitutions at 
position 173 and 277 were analysed with two separate polymerase chain reactions followed 
by restriction fragment length polymorphism analysis. The forward and reverse primers used 
for the PCR to detect the A173G substitution were 5'-CAGTTCTCTCATGGCTCGCA-3' and 
5'-GTGTGGCTGTAGAGATCATATGCT-3', respectively. The PCR conditions were 4 min 
at 95ºC, then 35 cycles of 30s at 95 ºC, 1 min at 58ºC, and 1 min at 72ºC, and finally an 
elongation step at 72 ºC for 7 min. A 750 bp product was amplified and aliquots of 5 μl of the 
PCR mixture were directly digested for one hour at 37°C with 10 units of the restriction 
enzyme AluI, followed by electrophoresis on 3% agarose gel, containing ethidium bromide. 
The UGT1A8*2 allele (A173G) contains only one restriction site for AluI, instead of two 
restriction sites for the UGT1A8*1 and UGT1A8*3 alleles (Figure 4.1a). To detect the C277Y 
substitution by PCR, the forward and reverse primers 5'-TCTTCATTGGTGGTATCAGCT-3' 
and 5'-AAAATTTGATAACTGATGAGTACATA-3' were used, respectively. The annealing 
temperature for this PCR was 1 min 49 ºC, with remaining similar PCR conditions. The last G 
of the forward primer creates a restriction sites for PvuII; the digestion of the 215 bp PCR 
product with PvuII was carried out under similar conditions as described above. The 
UGT1A8*3 allele (C277Y) contains no restriction site for PvuII, distinct from the UGT1A8*1 
and UGT1A8*2 alleles, which have one PvuII restriction site (Figure 4.1b). 
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M            1            2 M          1           2           3 
660 bp
440 bp
220 bp
90 bp
a b
195 bp 
215 bp 
Figure 4.1. Identification of UGT1A8 polymorphisms using restriction fragment length 
polymorphism analysis. Electrophoresis patterns of PCR fragments after digestion with AluI 
for the A173G polymorphism (a) and after digestion with PvuII for the C277Y polymorphism 
(b). M: 100 bp marker, lanes 1: homozygosity for the common allele, lanes 2: heterozygosity, 
lane 3: homozygosity for the variant allele. Homozygosity for the C277Y polymorphism was 
not found. The sizes of the PCR fragments are indicated by arrows.  
 
Statistical analyses 
Data were analysed by SAS version 8.0. Differences in the baseline characteristics of patients 
and controls were estimated with Fisher Exact test and t-test. Chi-square statistics was used to 
estimate differences in the presence of allele frequencies in UGT1A1, UGT1A6 and UGT1A8 
among the different study groups. When one of the genotypes has expected counts less than 
five, the Chi-square test may not be a valid test, and than we used Fisher Exact test. Odds 
ratios (OR) with 95% confidence interval (95% CI) were calculated by logistic regression 
analysis for the allele frequencies in UGT1A1 and for the UGT1A8*3 compared to the 
UGT1A8*1 and UGT1A8*2 alleles taken together. 
The distribution of each allele frequency among the control population was tested whether it 
fitted the Hardy-Weinberg equilibrium. 
In total, three genetic polymorphisms of the UGT1A family were analysed. Because the 
different UGT1A isoforms are derived from one single gene locus, we corrected for multiple 
testing with Bonferroni, meaning that P-values of less than 0.017 instead of 0.05 were 
considered to represent statistical significance.  
Finally, we examined the co-occurrence of the alleles encoding less active UGT enzymes, 
UGT1A*28, UGT1A6*2 and UGT1A8*3 among CP patients and control subjects using 
Spearman rank correlation test. 
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RESULTS 
 
Characteristics of patients and controls 
Characteristics of patients with CP and healthy controls are denoted in Table 4.1. There is a 
difference in gender between patients and healthy controls, with more female subjects in the 
latter group (P < 0.05; Table 4.1). 
The mean age of CP patients is higher compared to that of the control group (P < 0.05; Table 
4.1), with an exception for the HCP patients, since these patients do develop CP at younger 
age than the other CP patients.  
Although data on smoking habits was only available from a limited number of subjects, 
significantly more ACP patients smoked compared to healthy controls (P < 0.05; Table 4.1). 
 
Table 4.1. Main characteristics of patients with chronic pancreatitis and healthy controls 
 
Characteristics 
HCP                    ACP                    ICP                    All patients          Controls 
 
n  
 
Gender 
      Male/Female 
 
Age (years) 
      Mean +/- SD 
 
Smoking 
      Yes/No 
      Unknown 
 
25                        153                       80                       258                       140 
 
 
9/16                     117/36*                 38/42                  164/94*                53/87 
 
 
38 +/- 21            51 +/- 9*                 48 +/- 17*            49 +/-14*             44 +/- 16 
 
 
8/6                      91/7                       31/11                  130/24                  68/45 
11                       55                           38                       104                       27 
HCP: Hereditary Chronic Pancreatitis; ACP: Alcoholic Chronic Pancreatitis; ICP: Idiopathic 
Chronic Pancreatitis; * = P-value < 0.05 as compared to control group 
 
UGT1A1, UGT1A6 and UGT1A8 polymorphisms 
All UGT polymorphisms investigated are summarized in Table 4.2. Allele frequencies of the 
polymorphisms in the three UGT1A genes investigated here are reported in Table 4.3.  
There were no statistical differences in the distribution of UGT1A1*1 and UGT1A1*28 alleles 
among patients with HCP, ACP, ICP separately or in all CP patients combined vs. healthy 
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control subjects (Table 4.3). We were unable to detect individuals carrying 5 or 8 TA repeats 
in the TATA box of the promotor. 
The distribution of the UGT1A6*1, UGT1A6*2 and UGT1A6 R184S alleles in the different 
CP patient groups and control subjects does not demonstrate any statistical difference either 
(Table 4.3). There were no individuals with a single T181A variant, whereas approximately 
2% of all subjects carried the single R184S variant. 
UGT1A8 genotyping did not show a different distribution of the UGT1A8*1, UGT1A8*2 and 
UGT1A8*3 allele among patients compared to healthy control subjects (Table 4.3). Since 
UGT1A8*1 and UGT1A8*2 alleles may have similar catalytic properties, we combined these 
alleles, but this did not yield in significant differences between CP patients and controls. No 
statistical difference was observed in the frequencies of the UGT1A8*3 allele (Table 4.3).  
In addition, the co-occurrence of UGT1A*28 and UGT1A6*2 polymorphism were examined 
and strong association was found in both the CP patient and control group (r = 0.66, P < 
0.0001 and r = 0.78, P < 0.0001, respectively). There was no statistically difference in the 
distribution of this combination of alleles between CP patients and healthy controls (P = 
0.58). Because of the relatively low frequency of UGT1A8*3 allele, the combination of all 
three alleles encoding for less active UGT enzymes was not examined. 
For each of the three UGT1A genes the distribution of the allele frequencies among the 
control population was separately tested and found to fit with the assumption of the Hardy-
Weinberg equilibrium.  
 
Table 4.2. Genetic polymorphisms in UGTs investigated here 
Polymorphism 
 
Allelic variation 
 
UGT1A1*1 
UGT1A1*28 
 
UGT1A6*1 
UGT1A6*2 
UGT1A6 R184S 
 
UGT1A8*1 
UGT1A8*2 
UGT1A8*3 
 
(TA)6TAA 
(TA)7TAA 
 
T181R184
A181S184
T181 S184
 
A173C277
G173C277
A173Y277
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Table 4.3. Allele frequencies of UGT1A1, UGT1A6 and UGT1A8 in patients with chronic 
pancreatitis and healthy controls 
 
Alleles 
HCP                     ACP                     ICP                      All patients           Controls 
(n=50)                  (n=306)                (n=160)                  (n=516)                 (n=282)  
 
UGT1A1 
            *1   
            *28  
 
           P-value * 
           OR (95% CI) 
 
UGT1A6 
            *1 
            *2 
            R184S  
 
            P-value * 
 
UGT1A8 
            *1 
            *2 
            *3 
 
            P-value* 
 
           OR (95% CI)** 
 
 
0.68                      0.67                      0.66                       0.66                       0.72 
0.32                      0.33                      0.34                       0.34                       0.28 
 
0.61                      0.23                      0.15                       0.14  
1.2 (0.6-2.3)         0.8 (0.6-1.5)         1.4 (0.9-1.8)          1.3 (0.9-1.8) 
 
 
0.65                      0.63                      0.65                       0.64                       0.64 
0.30                      0.34                      0.34                       0.34                       0.34 
0.04                      0.03                      0.01                       0.02                       0.02 
 
0.64                      0.89                      0.48                       0.99 
 
 
0.82                      0.79                      0.83                       0.80                       0.73 
0.16                      0.20                      0.15                       0.18                       0.25 
0.02                      0.01                      0.02                       0.02                       0.01 
 
0.35                      0.33                      0.04                       0.06 
 
0.8 (0.2-12.9)       1.1 (0.3-4.4)         1.3 (0.3-6.0)          1.1 (0.3-3.7) 
HCP: Hereditary Chronic Pancreatitis; ACP: Alcoholic Chronic Pancreatitis; ICP: Idiopathic 
Chronic Pancreatitis; *: P-values, estimated with Chi-square test or with Fisher exact test, 
when cells have expected counts less than 5. OR: Odds Ratio, 95%CI: 95% Confidence 
Interval; **: OR 95%CI for the UGT1A8*3 allele compared to the UGT1A8*1 and 
UGT1A8*2 alleles taken together. 
 
 
DISCUSSION 
 
Genetic variations that may reduce expression or activity of phase II biotransformation 
enzymes are of toxicological and physiological importance and are frequently associated with 
a wide variety of diseases. Glucuronidation catalysed by UGTs is one of the most important 
mechanisms involved in host defence against xenobiotic chemicals and endogenous toxins. 
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Xenobiotically or endogenously-mediated cellular injury might play a role in the aetiology of 
CP [37-39]. In the present study we investigated the possible association between CP and 
genetic polymorphisms in three UGT1A isoenzymes that are associated with changes in 
enzyme activity and function and are potentially expressed in pancreatic tissue [20,25-
27,30,31]. 
We found that frequencies of genetic polymorphisms in UGT1A1, UGT1A6 and UGT1A8 in 
Caucasian healthy control subjects were not different to those in CP patients. This suggests 
that individuals bearing the UGT alleles, encoding for less active enzymes do not have a 
higher risk for developing CP. 
The frequency of the UGT1A1*28 allele was 34% in CP patients compared to 28% in the 
controls. This is comparable to the frequencies (29%-39%) reported in Caucasian control 
subjects by several other groups [27,30,40-42]. The frequency of the UGT1A6*2 allele in both 
CP patients and healthy controls was estimated at 34%, which is appreciably higher than the 
16.8% reported by Ciotti et al. [31], but not different from 30.7% and 32.5% found by Lampe 
et al. [30] and Köhle et al. [42], respectively. The allele frequency of UGT1A8*3, 1.6% for 
CP patients and 1.4% for healthy controls, was similar to 2.2%, reported by Huang et al [20].  
UGT1A7 is the only other member of the UGT1A family, which was recently investigated in 
relation to pancreatic diseases. Genetic polymorphisms possibly associated with a low 
detoxification activity of UGT1A7 have recently been identified by Ockenga et al. as a risk 
factor for alcohol induced CP and pancreatic carcinoma [34]. They detected a much higher 
frequency of the UGT1A7 allele in patients (25-37%) as compared to healthy controls (21%). 
As UGT1A7 catalyses the glucuronidation of several tobacco carcinogens, and smoking in 
addition to alcohol abuse, appears to be a risk factor for CP, reduced enzyme activity might 
confer a higher risk for ACP. In addition, the UGT1A7 is reported to be the predominant 
UGT1A transcript in human pancreas [34]. In contrast to Ockenga et al., who did find a 
positive association between the low detoxification allele UGT1A7*3 and the risk for 
alcoholic chronic pancreatitis and pancreatic cancer, results from our laboratory indicate that 
individuals bearing less active UGT1A7 alleles do not run a higher risk for pancreatic diseases 
(Chapter 5). We collected a large multi-national cohort of patients with either acute (n = 153) 
or chronic pancreatitis (idiopathic/hereditary n = 266, alcoholic n = 318) or pancreatic cancer 
(n = 297) and compared the genetic polymorphisms in the UGT1A7 gene with 1532 controls. 
Using melting curve analysis with fluorescence resonance energy transfer probes and 
restriction fragment length polymorphism analysis we were unable to detect differences in the 
UGT1A7 frequency distribution between patients and controls. Most notably, the frequency 
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of the UGT1A7*3 risk allele was comparable between patients (31-44%) and controls (40%). 
The discrepancies between our study and that of Ockenga et al. [34] most likely stems from 
differences in (a) selection of the control group (b) sample size and (c) the different 
methodology used in both studies. The UGT isoenzymes UGT1A1 and UGT1A6, investigated 
in our study do not specifically glucuronidate benzo[a]pyrenes or other toxic compounds from 
cigarettes [8], whereas UGT1A8 does [20]. However, it is not known yet whether the 
UGT1A8 enzyme is substantially expressed in pancreatic tissue. 
UGTs are known to exist as a superfamily of enzymes with a broad substrate profile, however 
substrate specificity of the various isoenzymes remains poorly defined. Isoenzymes may 
exhibit overlapping substrate specificity's, and one isoenzyme may compensate low activity of 
another, explaining why individuals bearing one low detoxification activity allele do not 
confer a higher risk for CP. Apparently the UGTs investigated here are not exclusively 
responsible for the metabolism of a particular drug or chemical associated with CP, or are not 
the predominant UGTs present in the cell as might be for UGT1A7 in the pancreas, and 
therefore these polymorphisms did not show to be of major clinical significance. 
Genetic polymorphisms in UGT1A1 and UGT1A6 are known to play important roles in 
disease susceptibility. Homozygosity for genetic polymorphisms in UGT1A1 may lead to 
hyperbilirubinemia (Crigler-Najjar or Gilbert's syndromes), because activity towards 
conjugation of bilirubin is restricted to UGT1A1 [17]. Nevertheless, the UGT1A1 promotor 
polymorphism, which is strongly linked to the UGT1A6 polymorphisms studied here [36], is 
reported to be positively associated with breast cancer in premenopausal African-American 
women, but not in Caucasians [40,43]. In addition, the UGT1A6*2 allele is found to be 
associated with reduced protection against colon adenomas by aspirin [32]. 
In summary, we failed to detect associations between CP and genetic polymorphisms in 
UGT1A1, UGT1A6 and UGT1A8 in Caucasians. Our results might suggest that presence of 
low detoxification activity of these UGT enzymes do not predispose to CP. 
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ABSTRACT 
 
Background: Xenobiotic-mediated cellular injury is thought to play a major role in the 
pathogenesis of pancreatic diseases. Genetic variations reducing the expression or activity of 
detoxifying phase II biotransformation enzymes such as the UDP-glucuronosyltransferases 
might be important in this respect. Recently, a UGT1A7 low detoxification activity allele, 
UGT1A7*3, has been linked to pancreatic cancer and alcoholic chronic pancreatitis. 
Methods: Genetic polymorphisms in the UGT1A7 gene were assessed in a large cohort of 
patients with different types of pancreatitis and pancreatic cancer originating from the Czech 
Republic (n = 93), Germany (n = 638), the Netherlands (n = 136), and Switzerland (n = 106), 
as well as in healthy (n = 1409) and alcoholic control (n = 123) subjects from these European 
countries. Polymorphisms were determined by melting curve analysis using fluorescence 
resonance energy transfer probes. Additionally, 229 Dutch subjects were analyzed by 
restriction fragment length polymorphism and 97 German subjects were analyzed by direct 
DNA sequencing. 
Results: The frequencies of UGT1A7 genotypes did not differ between patients with acute or 
chronic pancreatitis as well as pancreatic adenocarcinoma and alcoholic and healthy control 
individuals. We found evidence that PCR bias due to uneven allele amplification caused by a 
T to G transversion (-57T>G) located within the chosen primer sequence probably account for 
the detected UGT1A7 differences in a recent other study. 
Conclusions: Our data suggest that, in contrast to earlier studies UGT1A7 polymorphisms do 
not predispose patients to the development of pancreatic cancer and pancreatitis. Moreover, 
the previously reported association is most probably based on genotyping errors or a relatively 
low UGT1A7*3 frequency in the control group. 
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INTRODUCTION 
 
Chronic pancreatitis (CP) and pancreatic cancer are common diseases in industrialized 
countries associated with considerable morbidity and mortality. The underlying causes of 
pancreatic inflammation and cancer are multifaceted including environmental as well as 
genetic factors [1]. 
Pancreatic adenocarcinoma represents the fifth most frequent cause of cancer-related death 
world-wide [2]. Diabetes, obesity, alcohol abuse, smoking, several chemicals such as gasoline 
and related compounds, as well as certain insecticides are known risk factors for pancreatic 
cancer [3,4]. 
Chronic pancreatitis shares risk factors with pancreatic cancer such as smoking and alcohol 
abuse, but in itself is also a risk factor for pancreatic adenocarcinoma [5]. A genetic 
predisposition to pancreatitis is supported by the identification of sequence alterations in the 
genes encoding cationic trypsinogen (PRSS1), the cystic fibrosis transmembrane conductance 
regulator (CFTR), and the serine protease inhibitor, Kazal type 1 (SPINK1) in patients with 
hereditary or idiopathic chronic pancreatitis [6,7,8,9]. Additionally, an increased frequency of 
SPINK1 mutations has been reported in patients with alcohol-related chronic pancreatitis 
[10,11]. 
It is suggested that additional genetic factors modify the susceptibility to the different types of 
pancreatitis and pancreatic cancer. Xenobiotic-mediated cellular injury has been hypothesized 
to be an important pathogenic mechanism in pancreatic diseases. Thus, genetic variations that 
reduce the expression or activity of detoxifying phase II biotransformation enzymes might 
represent a risk factor for pancreatitis and pancreatic cancer [12]. 
Uridine 5'-diphosphate (UDP)-glucuronosyltransferases (UGTs) catalyze the addition of a 
glucoronyl group to a wide variety of endogenous and exogenous hydrophobic compounds to 
form water soluble glucuronides and enhance renal or biliary metabolite excretion. UGTs 
constitute a major cellular defense mechanism against xenobiotic chemicals and endogenous 
toxins [13,14,15] and contribute to the detoxification of known human carcinogens, such as 
heterocyclic amines as well as heterocyclic and polycyclic hydrocarbons [16]. 
UGTs are classified on the basis of sequence homology into the UGT1A, UGT2A, and 
UGT2B subfamilies [17]. Subfamily 1A isoforms are derived from a single gene locus on 
chromosome 2q37 [18]. In humans, UGT1A is composed of at least nine functional proteins 
(UGT1A1, UGT1A3-UGT1A10), which are encoded by five exons. Exons 2 to 5 are shared 
by all UGT1A proteins. Thus, the separate UGT1A forms consist of unique N-terminals and a 
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conserved 246-amino acid C terminus [19]. Each of these UGT1A forms possesses a 
distinctive substrate specificity [20]. 
Recently, functional polymorphisms in various genes encoding UGT1 family members have 
been discovered [21,22,23,24,25]. UGT1A7 is highly polymorphic and so far at least 11 
variants in 4 different codons have been characterized. These missense variants have been 
detected in codon 115, 129, 131, 139, and 208. This results in 11 polymorphic alleles 
(UGT1A7*1 *2, *3, *4, *5, *6, *7, *8  *9, *10, *11). The nomenclature of these allelic 
variants reflects the chronological order in which they were discovered (Figure 5.1).  
Human UGT1A7 is an extrahepatic enzyme expressed in pancreas, lung, esophagus, and 
stomach. UGT1A7 catalyses the glucuronidation of phenols, benzo[a]pyrenes, coumarines 
and steroid hormones [16,27]. Case control studies have suggested that polymorphisms 
leading to a low UGT1A7 detoxification activity are associated with cancer of the colon, liver 
and oral cavity [28,29,30]. Most notably, the UGT1A7*3 allele, which carries the lowest 
UGT1A7 detoxification activity, has been reported as a significant risk factor for pancreatic 
cancer and alcoholic chronic pancreatitis [31]. 
These data suggest that UGT1A7 polymorphisms may contribute to the risk of pancreatitis and 
pancreatic cancer. Therefore, we investigated this association in a large cohort of Caucasian 
pancreatitis and pancreatic cancer patients of Czech, Dutch, German, and Swiss origin. 
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Figure 5.1. UGT1A7 polymorphisms 
Figure 5.1 depicts 11 allelic variants of the UGT1A7 gene. Each block represents a base 
triplet with the corresponding amino acid. The variants detected so far have been detected in 
codon 115, 129, 131, 139, and 208 and are indicated on top. UGT1A7*1 represents the wild 
type while the other variants are numbered from UGT1A7*2 to UGT1A7*11. The base pair 
and amino acid that are different from wild type have been underlined. For UGT1A7*2 
through UGT1A7*11 only the changed codons are indicated. The different signs indicate: § 
not found in our study population, # not investigated in this study, &novel detected alleles 
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METHODS 
 
Subjects 
The study was approved by the local medical ethical review committee at each participating 
center and all subjects gave their informed consent. The study included patients from Czech 
Republic (n = 93), Germany (n = 638), the Netherlands (n = 136), and Switzerland (n = 106) 
(Table 5.1). A total of 973 consecutive patients were recruited in the different centers and 
blood samples were taken during a routine visit. Patient information was received by a 
structured questionnaire in their own mother tongue. 
The alcoholic chronic pancreatitis (ACP) group consisted of 318 patients. We also enrolled 
266 patients with non-alcoholic CP (idiopathic or hereditary CP) in our study. The clinical 
diagnosis of CP was based on two or more of the following criteria: presence of typical 
history of recurrent pancreatitis, radiological findings such as pancreatic calcifications and/or 
pancreatic ductal irregularities revealed by endoscopic retrograde pancreaticography or 
magnetic resonance imaging of the pancreas. Hereditary CP was diagnosed when two first-
degree relatives or three or more second-degree relatives, suffered from recurrent acute 
pancreatitis or chronic pancreatitis without no apparent precipitating factor. Alcohol-induced 
CP was diagnosed in patients who consumed more than 60 g (females) or 80 g (males) of 
ethanol per day for more than two years. Patients were classified as having idiopathic CP 
when precipitating factors such as alcohol abuse in amounts as described above for alcoholics, 
trauma, medication, infection, metabolic disorders and/or a positive family history, all were 
absent. 
The acute pancreatitis (AP) patients group consisted of 153 (101 males, 52 females) German 
patients of alcoholic (n = 42), biliary (n = 63), idiopathic (n = 23) or various (n = 25) origin. 
Acute pancreatitis was defined as acute abdominal pain with a typical clinical picture and 
serum amylase concentration at least three times the upper limit of normal and typical 
findings on sonography or computed tomography [31]. 
We included also 236 patients with histological confirmed pancreatic adenocarcinoma (PC) of 
German (n = 201) and Swiss (n = 35) extraction in this study. As control subjects served 
medical students or staff and participants of the BASE study (Berlin aging study) (German 
controls), blood donors (Swiss controls), randomly selected healthy newborns (Czech 
controls), or individuals recruited by advertisement in a local paper (Dutch controls). Controls 
originated from the Czech Republic (n = 319), Germany (n = 432), the Netherlands (n = 275), 
and Switzerland (n = 383) (Table 5.1) from the catchments population of the patients. The 
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control individuals volunteered without a set reward and no selective criteria were applied. In 
addition, we examined two additional control groups consisting of alcoholic subjects without 
pancreatic disease (n = 123) of German (n = 30) and Dutch (n = 93) descent (Table 5.1) 
recruited from a detoxification unit because of their addiction. We defined alcoholics as 
subjects if they consumed more than 60 g (females) 80 g (males) of ethanol respectively per 
day for more than two years. None of the alcoholics had CP or another known end-organ 
damage associated with alcoholism. 
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Genotyping 
For DNA extraction, blood samples were collected into EDTA tubes and stored at –20°C until 
use. DNA was isolated from whole blood using the Pure Gene or Qiagen DNA isolation kit 
according to the instructions from the manufacturers (Gentra Systems, Minneapolis, 
Minnesota, USA and Qiagen, Hilden Germany). 
We screened for the mutations in codons 129, 131 and 208. Primers flanking the 
polymorphisms of interest in exon 1 of UGT1A7 and fluorescence resonance energy transfer 
(FRET) probes were synthesized based on the published nucleotide sequence (GenBank 
#U39570). Primer sequences (S and A [Table 5.2]) used for polymerase chain reaction (PCR) 
were described by Köhle et al. [32]. We performed PCR using 0.5 U AmpliTaq Gold 
(Applied Biosystems), 400 µM dNTPs, 1.5 mM MgCl2 and 0.1 µM of each primer in a final 
volume of 25 µl. The reaction mix was denatured at 95°C for 12 minutes followed by 48 
cycles of denaturation at 95°C for 20 seconds, annealing at 56°C for 40 seconds, elongation at 
72°C for 90 seconds, and a final extension step for 2 minutes at 72°C in an automated 
thermocycler. For haplotype analysis, we performed allele specific PCR in 168 individuals 
using primers 3/4F and R with a annealing temperature at 60°C (Table 5.2). 
Genotyping of UGT1A7 alleles was carried out by melting curve analysis with FRET probes 
in the LightCycler (Roche Diagnostics, Mannheim, Germany). For detection of the 
polymorphisms at codons 129 and 131 the sensor probe was 5’-LC 640-
TTAAGTATTCTACTAATTTTTTGTCCTT-ph (LC: LightCycler Red attached to 5' 
terminus; ph: phosphate) and the anchor probe 5’-
GGATCGAGAAACACTGCATCAAAACAACTCTCC-FL (FL: 5,6-carboxyfluorescein 
attached to 3'-O-ribose) were used. For identification of the W208R polymorphism the 
sequence of the sensor probe was 5'-TGATGTGGTTCCGTACTCTCTCCTT-FL and of the 
anchor probe was 5'-LC 705-AAAGTCATGGCGTCTGAGAACCCTAAG-ph. Both sensor 
probes were complementary to the mutant sequences (129K/131K and 208R, respectively). 
During melting curve analysis, a more stable duplex with the mutant allele than with the wild-
type allele was formed, resulting in an allele-specific melting curve (N129K/R131K: 58 °C 
vs. 47°C; W208R: 65°C vs. 60.5°C). The program for analytical melting was 95°C for 60 s, 
38°C for 40 s, and an increase to 75°C at a 0.1 °C/s ramp rate. All FRET probes were 
designed and synthesized by TIB MOLBIOL, Berlin, Germany. 
Additionally, we performed in 229 Dutch samples RFLP (restriction fragment length 
polymorphism) analysis. To detect the variations at codon 129/131, we use the forward 
primers F1 and F2 and the reverse primer R1 (Table 5.2). F1 detects only the N129K/R131K 
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mutation, F2 detects the N129K/R131K and N129R/R131K mutations. After digestion of the 
PCR product with Vsp I the following fragments can be found: wild-type: 315 + 18 bp; 
heterozygotes: 333 + 315 + 18 bp; homozygotes: 333 bp. To detect the W208R alteration, we 
use the forward primer F3 and reverse primer R2 (Table 5.2). After digestion of the PCR-
product with Rsa I the following fragments can be found: wild-type: 440 bp; heterozygotes: 
440 + 337 + 103 bp; homozygotes: 337 + 103 bp. To determine whether the N129K/R131K 
or N129R/R131K and W208R occur cis or trans, we use the allele specific primers F4 and R1 
(Table 5.2). After digestion of the PCR-product with Rsa I the following fragments would be 
expected: *1/*3: 253 + 79 bp; *2/*4: 332 bp. 
To further ascertain the reliability of our results, we repeated genotyping with FRET probes 
by performing 7 extra PCR assays using different primer combinations. We analyzed 240 
individuals using the primer combinations F and 208R, and 48 controls using the primer 
combinations F3 and R1, Fn and R, S and R1, 129/131F and 208R, 129/131F and 129/131R, 
and 208F and 208R, respectively (Table 5.2). Moreover, genotypes of 60 samples were 
confirmed by bi-directional DNA sequencing. 
In addition, we investigated 37 CP patients with an N34S SPINK1 variation obtained from 
Volker Keim (Leipzig, Germany), which were previously analyzed in the report of Ockenga 
and co-workers [31]. We analyzed these 37 individuals by melting curve analysis using the 
primer combinations S and A, F and 208R, 129/131F and 208R, 3/4F and 208R, Fn and Rx, -
57T-F and R, -57G-F and R, -57Tclamp-F and R, and -57Gclamp-F and R, respectively 
(Table 5.2). Moreover, we performed DNA sequencing of these 37 patients after PCR 
amplification by the primer pair Fn and Rx. 
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Statistics 
Data were analyzed by SAS version 8.0. Differences in the baseline clinical characteristics of 
patients and control groups were estimated with Fisher's exact test and t-test. Chi-square 
statistics or Fisher's exact test were used to estimate differences of the UGT1A7 alleles among 
the different study groups. Odds ratios (OR) with 95% confidence interval (95% CI) were 
calculated by logistic regression analysis for the allele frequencies and genotype distribution 
in UGT1A7 taking possible confounding factors as age, gender and country of origin into 
account. 
The distribution of UGT1A7 polymorphisms among the control populations was tested 
whether they were in the Hardy-Weinberg equilibrium. 
 
RESULTS 
 
Characteristics of patients and controls 
Table 5.1 lists the characteristics of patients with CP, PC and healthy controls. There is a 
small, albeit significant difference regarding gender distribution between alcoholic chronic 
pancreatitis and acute pancreatitis patients and healthy controls, with relatively more female 
subjects in the latter group (P < 0.05). In the German and Swiss population, the mean age of 
pancreatic cancer patients is higher compared to that of the control group (P < 0.05). The 
hereditary CP patients are significantly younger than the control subjects, as these patients 
develop CP at a younger age compared to patients with other pancreatic diseases (P < 0.05). 
 
UGT1A7 polymorphisms 
No statistical differences in the distribution of the UGT1A7 genotype among all patient and 
control groups were observed (OR = 0.99, 95%CI: 0.1-2.4) (Table 5.3), except for the 
German pancreatic adenocarcinoma patients. Here, a significant difference was found with 
respect to UGT1A7 genotypes, which was due to the relatively high prevalence of the *2/*3 
genotype compared to the control group. Likewise, the UGT1A7 genotype distribution did not 
differ among the various ethnic control groups (P = 0.20). To assess the impact of alcoholism, 
we compared Dutch and German ACP patients with a control group consisting of alcoholics 
without pancreatic diseases of similar ethnic origin. Again, we observed no significant 
difference in genotype distribution. 
As expected, the ratio of UGT1A7 allele frequencies was similar in the different patient and 
control groups (OR = 0.9, 95%CI: 0.8-1.1 ) (Table 5.4). In contrast to genotype distribution, 
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the allele frequency was similar in the German pancreatic adenocarcinoma group. 
Comparison of the allele frequencies in ACP patients with that of alcoholic control subjects as 
well as with healthy control individuals of Dutch and German origin did not demonstrate any 
difference. We did not detect any individual carrying the UGT1A7*4 allele, but detected two 
novel rare alleles: R129-K131-R208 (UGT1A7*10) and N129-Q131-W208 (UGT1A7*11) 
(Figure 5.1). The extra analyses with RFLP of 229 Dutch samples demonstrated the same 
results as we found with the FRET analysis. Discrimination of UGT1A7*1/*3 from 
UGT1A7*2/*4 heterozygotes revealed that all investigated individuals carried the 
UGT1A7*1/*3 alleles and none the UGT1A7*2/*4 alleles. 
The results of the genetic analyses of 37 N34S SPINK1 mutated CP patients, which had been 
analyzed and published by Ockenga and co-workers [31] differed in 14 cases (38%) (Table 
5.5). Our analysis showed that 11 out of 12 individuals carrying UGT1A7*1/*3 were 
classified in that paper as having UGT1A7*1/*4 alleles. Sequencing of exon 1 by primers 
located upstream (Fn) respectively downstream (Rx) of the primer oligonucleotides used by 
the Ockenga et al. group (F and R) revealed a T>G transversion at position -57, which appears 
to be in complete linkage disequilibrium with UGT1A7*3 (K129-K131-R208) (Table 5.5). 
This base pair change is within the sequence of the forward primer (at position -19 away from 
the 3'-end of the primer) used by Ockenga et al. (Figure 5.2). PCR amplification of 
UGT1A7*1/*3 heterozygotes at an annealing temperature of 52°C with forward primers that 
contained either a T (-57T-F and -57Tclamp-F) or a G (-57G-F and -57Gclamp-F) at position 
-57 resulted in a reduced amplification of the heterozygous allele with one mismatch. With 
higher annealing temperatures (56°C and 60°C), only the complete complementary allele was 
amplified in heterozygotes (data not shown).  
 
 
 
 
primer chosen in ref. 31           5'-G CGGCTCGAGC CACTTACTAT ATTATAGGAG CT-3' 
UGT1A7 sequence  -80 GGTTCTATCT GTACTTCTTC CACTTACTAT ATTATAGGAG CTTAGAATCC -31 
       -57T>G 
 
Figure 5.2. UGT1A7 -57T>G polymorphism 
The first line shows the forward primer used by Ockenga et al. [31]; the second line the 
genomic sequence of UGT1A7. The GC-rich clamp at the 5'-end of the primer that does not 
align with the UGT1A7 sequence is underlined. The position of the mutated nucleotide is 
indicated in bold. 
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Table 5.5. Different genotyping results in the same patients analyzed in the present and a 
previous study [31] 
 
Patient S + A F + 208R 129F + 
208R 
3/4F + 208R Fn + Rx Ockenga 
et al. [31] 
-57 T/G 
 
D-L-0011 1/3 (2/4) 1/3 (2/4) 1/3 (2/4) 1/3 1/3 (2/4) 1/4 -57 Tg
D-L-0015 3/3 3/3 3/3 3/3 3/3 2/3 -57 gg
D-L-0021 1/2 1/2 1/2 1/2 1/2 1/2 -57 TT
D-L-0030 1/3 (2/4) 1/3 (2/4) 1/3 (2/4) 1/3 1/3 (2/4) 1/4 -57 Tg
D-L-0031 2/2 2/2 2/2 2/2 2/2 2/2 -57 TT
D-L-0047 1/3 (2/4) 1/3 (2/4) 1/3 (2/4) 1/3 1/3 (2/4) 1/4 -57 Tg
D-L-0074 2/3 2/3 2/3 2/3 2/3 2/3 -57 Tg
D-L-0099 1/3 (2/4) 1/3 (2/4) 1/3 (2/4) 1/3 1/3 (2/4) 1/4 -57 Tg
D-L-0100 1/3 (2/4) 1/3 (2/4) 1/3 (2/4) 1/3 1/3 (2/4) 1/3 (2/4) -57 Tg
D-L-0103 3/3 3/3 3/3 3/3 3/3 3/3 -57 gg
D-L-0115 2/3 2/3 2/3 2/3 2/3 2/3 -57 Tg
D-L-0116 1/2 1/2 1/2 1/2 1/2 1/2 -57 TT
D-L-0131 1/2 1/2 1/2 1/2 1/2 1/2 -57 TT
D-L-0134 3/3 3/3 3/3 3/3 3/3 2/3 -57 gg
D-L-0142 1/2 1/2 1/2 1/2 1/2 1/2 -57 TT
D-L-0148 2/3 2/3 2/3 2/3 2/3 2/3 -57 Tg
D-L-0155 1/1 1/1 1/1 1/1 1/1 1/1 -57 TT
D-L-0166 2/3 2/3 2/3 2/3 2/3 1/3 (2/4) -57 Tg
D-L-0169 1/3 (2/4) 1/3 (2/4) 1/3 (2/4) 1/3 1/3 (2/4) 1/4 -57 Tg
D-L-0190 1/3 (2/4) 1/3 (2/4) 1/3 (2/4) 1/3 1/3 (2/4) 1/4 -57 Tg
D-L-0212 1/3 (2/4) 1/3 (2/4) 1/3 (2/4) 1/3 1/3 (2/4) 1/4 -57 Tg
D-L-0213 3/3 3/3 3/3 3/3 3/3 3/3 -57 gg
D-L-0219 1/2 1/2 1/2 1/2 1/2 1/2 -57 TT
D-L-0221 2/3 2/3 2/3 2/3 2/3 2/3 -57 Tg
D-L-0226 3/3 3/3 3/3 3/3 3/3 3/3 -57 gg
D-L-0247 2/3 2/3 2/3 2/3 2/3 2/3 -57 Tg
D-L-0251 1/1 1/1 1/1 1/1 1/1 1/1 -57 TT
D-L-0272 1/1 1/1 1/1 1/1 1/1 1/1 -57 TT
D-L-0374 1/3 (2/4) 1/3 (2/4) 1/3 (2/4) 1/3 1/3 (2/4) 1/4 -57 Tg
D-L-0404 3/3 3/3 3/3 3/3 3/3 3/3 -57 gg
D-L-0439 1/1 1/1 1/1 1/1 1/1 1/1 -57 TT
D-L-0454 1/3 (2/4) 1/3 (2/4) 1/3 (2/4) 1/3 1/3 (2/4) 1/4 -57 Tg
D-L-0475 3/3 3/3 3/3 3/3 3/3 3/3 -57 gg
D-L-0516 1/1 1/1 1/1 1/1 1/1 1/1 -57 TT
D-L-0528 1/3 (2/4) 1/3 (2/4) 1/3 (2/4) 1/3 1/3 (2/4) 1/4 -57 Tg
D-L-0535 1/3 (2/4) 1/3 (2/4) 1/3 (2/4) 1/3 1/3 (2/4) 1/4 -57 Tg
D-L-0537 1/2 1/2 1/2 1/2 1/2 1/2 -57 TT
 
Comparison of genotyping results of 37 patients analyzed and published in the previous report 
[31]. Genotypes obtained in the present study using different primer combinations (S + A, F + 
208R, 129F + 208R, 3/4F + R, Fn + Rx) are given in column 2 to 6. Genotypes obtained by 
Ockenga et al. are given in column 7. Column 8 shows the -57T>G transversion linked with 
UGT1A7*3. 
Differences in genotyping are marked bold in column 7. 
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DISCUSSION 
 
Glucuronidation catalyzed by UGTs is one of the most important mechanisms involved in the 
host defense against xenobiotic chemicals and endogenous toxins. Xenobiotic-mediated 
cellular injury is thought to represent a major pathogenic factor in pancreatic diseases 
[13,14,15]. In the present study, we investigated the relationship between pancreatic cancer as 
well as pancreatitis and UGT1A7 polymorphisms in codons 129, 131 and 208 that have been 
associated with altered enzyme activity (Figure 5.1) [21,24,26]. The frequencies of the 
different UGT1A7 alleles in the control subjects were similar to those observed in patients 
with pancreatic adenocarcinoma and different types of acute and chronic pancreatitis. These 
findings indicate that individuals carrying less active UGT1A7 alleles do not run at a higher 
risk for pancreatic diseases. This study controls for potential confounders such as age, gender 
and country of origin. However, because of lack of detailed data, we could not control for 
certain life style factors as smoking, dietary habits, and medication. In prospective studies we 
recommend to control for these possible confounding factors as well. 
Our results differ from those published recently by Ockenga and colleagues. In this study, the 
authors identified the low detoxification allele UGT1A7*3 as a risk factor for alcoholic 
chronic pancreatitis and pancreatic cancer [31]. This study analyzed 52 patients with 
pancreatic cancer and 63 patients with alcoholic CP, while we investigated a larger cohort of 
almost 1,000 patients and more than 1,500 control subjects originating from 4 different 
European countries. The control subjects were recruited from the same population as patients 
to minimize confounding effects of ethnic variations and environmental exposures. 
There may be several reasons the different findings. First, the differences between our results 
and those published earlier can be in part explained by the relatively low frequency of the 
UGT1A7*3 allele in control subjects in the latter study [31]. We detected a frequency of the 
UGT1A7*3 allele of about 40% in healthy controls, which is in line with the frequencies of 
32%, 36% and 37% in Caucasian control subjects reported by other researchers [25,26,32], 
but appreciably higher than the 16%-21% described by Ockenga et al [28,29,31,33]. It is 
worth noting that in prior studies on associations between the UGT1A7*3 polymorphism and 
other diseases such as hepatocellular carcinoma or colon cancer, the latter group detected a 
frequency of the UGT1A7*3 allele in patients that varied between 31% and 44% 
[28,29,30,31,33]. Consequently, the association between UGT1A7*3 with pancreatic diseases, 
and perhaps for their studies with hepatocellular and colon cancer as well, might be attributed 
to the relatively low UGT1A7*3 frequency in the control group of these studies. 
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In contrast to several earlier studies of the same group, who detected a UGT1A7*4 allele 
frequency up to 11% [28,29,31,33], we failed to detect the UGT1A7*4 allele in any of about 
2,500 investigated Caucasian subjects, although we specifically searched for it. These results 
are in line with other investigators, who were also unable to detect the UGT1A7*4 allele in 
their samples [32,34]. Only one other group reports a frequency of the UGT1A7*4 allele of 
1% to 3%, [25,30] but these latter studies did not take account of the novel detected 
UGT1A7*10 and UGT1A7*11 alleles. We suspect that in these studies the UGT1A7*10 allele, 
which was demonstrated in our study populations in a frequency of 1% to 2%, might have 
been interpreted as being a UGT1A7*4 allele. 
As N129K/R131K or N129R/R129K and W208R may occur in cis or trans, UGT1A7*1/*3 
heterozygotes are indistinguishable from UGT1A7*2/*4 heterozygotes by all genotyping 
approaches used in the literature reported to date. In order to address this problem, we 
performed two different allele specific PCR assays. First, we amplified exclusively the 
UGT1A7*3 and UGT1A7*4 alleles with specific primers to the codon 11 polymorphism 
(CCC>CCA) which is described to be in complete linkage disequilibrium with the W208R 
alteration and analyzed the 129/131 and 208 polymorphisms by melting curve analysis. 
Secondly, we amplified solely the UGT1A7*2 and UGT1A7*3 alleles with oligonucleotides 
which are specific to the codon 129 & 131 polymorphisms and analyzed W208R by RFLP 
analysis. With both approaches all individuals were consistently genotyped as UGT1A7*1/*3 
and none were found to be UGT1A7*2/*4 compound heterozygote.  
As a consequence we surmise that the high frequency of UGT1A7*4 alleles in the recent 
study published in the Journal might be due to dissimilarities in interpretation of the genotype 
results. The authors describe overall UGT1A7 allele frequencies, but do not provide detailed 
data on the distribution of the single allele combinations [31]. A reappraisal of genetic data 
formerly reported by the same group [28], reveals disequilibrium of UGT1A7 genotype 
distribution in their control population. For example, in their report 20% of 210 control 
subjects were homozygous for UGT1A7*1 (12-14% in our controls) and nearly the same 
proportion (17%) were compound heterozygous for UGT1A7*1/*4. In contrast, 8% were 
homozygous for UGT1A7*3 (15-21% in our controls), but none of the controls was 
compound heterozygous for UGT1A7*3/*4 [28]. These data either suggest a biased selection 
of control subjects or might reflect a methodological problem. 
To examine the possibility that differences arose from PCR amplification bias, we analyzed 
selected samples using the primers described by these researchers as well as slightly modified 
primers [29]. Performing PCR with these primers, we found a low amplification of mutant 
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129/131 in the presence of a heterozygous UGT1A7*3 allele, which inaccurately suggests the 
presence of UGT1A7*1/*4 instead of the actual UGT1A7*1/*3 genotype (Figure 5.3a, marked 
by arrows). This contrast with the results obtained by PCR amplification using the primers 
published by Köhle et al. (Figure 5.3b) or obtained by PCR amplification using 6 other primer 
combinations designed by us (data not shown). 
DNA sequencing of 37 CP patients with a SPINK1 N34S mutation, which were previously 
analyzed and published [31] revealed a T>G base pair change at position -57 of the ATG 
initiation codon. This polymorphism appears to be in complete linkage disequilibrium with 
UGT1A7*3 (K129-K131-R208) and was detected both in a heterozygous or homozygous state 
in all UGT1A7*3 heterozygotes or homozygotes, respectively, but not in individuals without a 
UGT1A7*3 allele. -57T>G is located within the sequence of the forward primer used by 
Ockenga et al. This single nucleotide polymorpism is located 19 nucleotides upstream from 
the 3'-end of the chosen primer and should not affect PCR amplification. However, the region 
downstream of -57 is extremely AT-rich making the 3'-end of the chosen oligonucleotide 
primer unstable. Moreover, a GC-rich clamp, which does not align with the UGT1A7 
sequence was attached at the 5'-end of this primer which further affects the affinity to its 
target (Figure 5.3). To examine the possibility that -57T>G affects PCR amplification, we 
designed several primers with either a T or a G at position -57. Subsequent melting curve 
analyses showed that in -57T>G heterozygotes primarily or exclusively the -57T or -57G 
allele was amplified depending on the chosen primer. Since -57T>G appears to be in cis with 
K129-K131-R208 (UGT1A7*3), this polymorphism reduces the amplification of the 
UGT1A7*3 allele in the presence of UGT1A7*1 or UGT1A7*2, and may confound the 
interpretation of the results.  
Consequently, the observed differences of the PCR amplification efficiency seem to be 
related to the selected primers, rather than method used for mutation detection. The genotype 
discrimination by the FRET probes used in our study was unambiguous with a temperature 
difference of 11°C for the N129K/R131K variation and 4.5°C for the W208R alteration 
(Figure 5.2). To further validate our results, we performed genotyping of 229 Dutch samples 
by RFLP analysis and obtained identical results compared to FRET analysis. We also 
confirmed our results by DNA sequencing of 60 selected samples. Thus, the described 
UGT1A7*4 allele most likely represents a laboratory artifact.  
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a                 b 
Figure 5.3. Genotyping of UGT1A7 129/131 polymorphisms with FRET probes. 
Fluorescence signal data were obtained during the melting transition of the fluorophore-
labeled detection probe from the amplified fragment. Fluorescence data were converted to 
derivative melting curves by plotting the negative derivative of the fluorescence with respect 
to temperature against temperature. 
a Genotyping of codons 129/131 using a modified primer pair published by Vogel et al. [29]. 
Curves: 1, homozygous wild-type sample (129N/131R) as found in UGT1A7*1 and 
UGT1A7*4; 2, homozygous mutant sample (129K/131K) as found in UGT1A7*2 and 
UGT1A7*3, 3, heterozygous samples displaying two peaks (129N/131R and 129K/131K). 
Low discrimination of heterozygous and wild-type samples due to reduced PCR amplification 
of the mutant allele (129K/131K) in heterozygous UGT1A7*3 individuals leading to 
UGT1A7*1/*4 instead of UGT1A7*1/*3 genotypes (marked by arrows). 
b Genotyping of codons 129/131 using the primer pair published by Köhle et al. [32]. 
 
In most of the studies UGT1A7 polymorphisms have been determined by direct DNA 
sequencing, which is generally accepted as "gold standard" for mutation detection and thought 
to be superior to other methods of mutation analysis. However, since sequencing requires 
PCR amplified DNA as template, uneven allele amplification during PCR will lead to 
erroneous findings in the subsequent sequencing reaction. The observed differences in 
UGT1A7 gene analysis can readily be explained by a primer-dependent PCR bias for the 
various alleles. Accordingly, as most analytical methods such as sequencing as the "gold-
standard", RFLP, TaqMan or hybridization probes depend on the ‘wrong’ primer generated 
PCR product, all will yield the same ‘wrong’ result. In this respect, our report represents an 
important methodological example how PCR amplification bias results in genotyping errors. 
The implications of this finding extend beyond analysis of UGT1A7 gene variants and may 
have impact on other genetic association studies. 
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Since the UGT1A7 gene is expressed exclusively in extrahepatic tissues of the gastrointestinal 
tract it might play an important role in first pass metabolism [21]. UGT1A7 has been detected 
in the mucosa of the mouth, the esophagus, stomach, lungs, and very recently in the pancreas 
and therefore seems to be a candidate gene influencing the risk for pancreatic diseases. There 
are inter-individual variations in expression of the UGT1A7, and other isoforms of UGTs may 
exhibit overlapping substrate specificity, explaining why individuals bearing a low 
detoxification activity allele do not confer a higher risk for pancreatic diseases. Unless the 
UGT in question is responsible for the exclusive metabolism of a particular drug or chemical, 
or is the predominant or only UGT present in the cell, it is unlikely that this polymorphism 
will be of major clinical significance. 
In summary, we did not detect any association between pancreatic diseases and UGT1A7 
polymorphisms. The previously reported association is most probably based on PCR 
amplification bias and/or a biased selection of control subjects. The presence of low 
detoxification activity UGT1A7 alleles such as UGT1A7*3 predisposes neither to pancreatic 
cancer nor to any type of acute or chronic pancreatitis. 
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ABSTRACT 
 
Background: The cause of chronic pancreatitis (CP) remains unknown. However, oxidative 
stress might play a role, since recent animal studies have demonstrated that oxygen free 
radicals contribute to the pathogenesis of experimental pancreatitis. Human serum 
paraoxonase (PON1) is an antioxidant enzyme that is proposed to protect against cellular 
damage from oxidative stress. Genetic variations, resulting in variable activity rates of this 
enzyme, are of toxicological and physiological importance. We investigated whether genetic 
polymorphisms of the PON1 gene modify the risk for CP. 
Methods: DNA samples were obtained from 236 adult CP patients of hereditary (n = 23), 
alcoholic (n = 137) or idiopathic (n = 76) origin. DNA from 113 healthy controls and from 93 
alcoholic controls was analysed for comparison. Patients and controls were all of Caucasian 
origin. Genetic polymorphisms (L55M and Q192R) in PON1 were determined by PCR, 
followed by restriction-fragment-length-polymorphism analyses in all subjects. 
Results: The frequencies of the PON1-55 alleles did not differ between CP patients and 
healthy controls. However, the PON1-192Q allele was significantly more common in 
idiopathic CP patients (OR = 1.5, 95%CI: 1.02-2.5) as compared to healthy controls. 
Conclusions: These data suggest that the PON1-192Q allele, resulting in partly deficient 
antioxidant and detoxification activity of this enzyme, might be a risk factor for idiopathic CP 
in Caucasians. 
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INTRODUCTION 
 
Chronic pancreatitis (CP) is a progressive irreversible inflammatory disease, which eventually 
leads to impairment of exocrine and/or endocrine function of the pancreas [1-4]. The 
underlying causes of CP are multi-faceted, and include environmental as well as genetic 
factors, but a complete understanding of the pathogenesis of CP is lacking [5]. Different 
hypotheses have been proposed, including oxidative stress of endogenous origin or chemical 
stress by environmental or lifestyle related xenobiotics [6-10]. 
There is growing recognition that an imbalance between reactive oxygen species (ROS) 
producing and ROS scavenging processes leads to the damage of pancreatic acinar cells, 
initiating auto-digestion of the entire pancreas. Experimental animal studies and evidence 
from clinical settings reinforce this hypothesis for pancreatitis [11-13]. 
Serum paraoxonase (PON1) is an enzyme proposed to play a protective role in various disease 
processes involving oxidative stress [14,15]. PON1 is synthesized in the liver and excreted 
into the circulation, where it associates to high-density lipoprotein (HDL). It is a phase I 
biotransformation enzyme that is able to hydrolyze lactones, organophosphate insecticides 
and nerve gases and inactivates pro-inflammatory oxidized lipids present in oxidized LDL 
[16], thus preventing oxidative modification of LDL in vitro. However, the physiological 
substrate of PON1, and with that its physiological role in vivo, remains to be clarified. PON1 
belongs to a paraoxonase gene family that is located on chromosome 7q21.3-q22.1 and 
contains at least 3 functional members, PON1, PON2 and PON3 [14,17,18]. The genetic basis 
of the inter-individual variability in PON1 activity has been attributed to the polymorphisms 
in the gene encoding for this enzyme [17]. 
PON1 may contain two common genetic polymorphisms, resulting in amino acid substitutions 
in the enzyme protein. The first involves a leucine/methionine (L/M) substitution at codon 55, 
which has an effect on PON1 protein levels in plasma by modulating PON1 mRNA levels. 
The PON1-55L allele may correspond to higher functional PON1 enzyme levels than the 
PON1-55M allele [19-21]. The second polymorphism involves a glutamine/arginine (Q/R) 
substitution at codon 192 and is the major determinant of the enzyme’s catalytic efficiency for 
a number of organophosphate substrates, including paraoxon [17,18]. The activity of the 
enzyme, however, depends on the substrate used. For example, the efficiency of the PON1-
192R allele to hydrolyse paraoxon is higher but the efficiency to hydrolyse diazoxon is lower 
than that of the PON1-192Q allele. Furthermore, the PON1-192R allele has been reported to 
possess lower ability for preventing the accumulation of lipid peroxides on LDL than the 
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PON1-192Q allele [18,22]. Thus, the antioxidative effect of PON1 may correlate inversely 
with paraoxonase activity and positively with diazoxonase activity. 
Numerous studies have reported on the relation between PON1 and the risk on coronary 
artery disease and ischemic stroke [18,23,24]. However, the association of the PON1 
genotype with antioxidant activity remains controversial [25].  
Since PON1 was shown to be expressed in pancreatic islets, this antioxidant enzyme might be 
involved in the pathophysiology of CP [26]. In addition, genetic polymorphisms in PON1 are 
known to modulate its enzyme activity, and therefore we investigated the possible association 
between CP and PON1 gene alleles, in a cohort of non-selected Caucasian CP patients. 
 
METHODS 
 
Subjects 
The study was approved by the local medical ethical review committee, and all subjects gave 
their written informed consent. All subjects studied were Caucasians of Dutch (50%) or 
Hungarian (50%) extraction. The CP patients group consisted of 236 adult patients (152 
males, 84 females). Twenty-three patients (10%) had a family history of CP (HCP), 137 
patients (58%) had alcohol induced CP (ACP) and 76 patients (32%) were classified as 
having idiopathic CP (ICP).  
The clinical diagnosis of CP was based on one or more of the following criteria: presence of 
typical complaints (recurrent upper abdominal pain, radiating to the back, relieved by leaning 
forward or sitting upright and increased after eating); suggestive radiological findings, such as 
pancreatic calcifications or pseudocysts, and pathological findings (pancreatic ductal 
irregularities and dilatations) revealed by endoscopic retrograde pancreaticography or 
magnetic resonance imaging of the pancreas before and after stimulation with secretin. HCP 
was diagnosed on the basis of two first-degree relatives or three or more second-degree 
relatives in two or more generations, which suffered from recurrent acute pancreatitis or 
chronic pancreatitis for which there was no precipitating factor. ACP was diagnosed in 
patients who consumed more than 60 g (females) or 80 g (males) of ethanol per day for more 
than two years. Three of the 137 ACP patients also have liver cirrhosis. Patients were 
classified as having ICP when precipitating factors such as alcohol abuse, trauma, medication, 
infection, metabolic disorders or a positive family history were all absent. 
For comparison, we included two control groups: one group consisting of 113 adult healthy 
subjects (43 males, 70 females) recruited by advertisement in a local paper and a group of 93 
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alcoholic subjects (64 males, 29 females), who were treated in a detoxification unit because of 
their addiction. We defined alcoholics as subjects who consumed in excess of 60 g (females) 
or 80 g (males) of ethanol per day for more than two years. None of the alcoholics had CP or 
other known end-organ diseases because of their alcoholism. 
 
Blood 
For DNA extraction, blood samples were collected into EDTA tubes and stored at –20 °C 
until use. DNA was isolated from whole blood using the Pure Gene DNA isolation kit 
according to the instructions from the manufacturer (Gentra Systems, Minneapolis, 
Minnesota, USA). DNA was diluted to a concentration of 50 milligram per millilitre and 
stored at 4 °C. 
 
Genotyping 
The polymorphisms in the PON1 gene corresponding with amino acid substitutions at 
positions 55 and 192, were analysed by polymerase chain reaction (PCR) followed by 
restriction fragment length polymorphism analysis. The forward and reverse primers used for 
the PCR to detect the L55M substitution were: 5'-GAAGAGTGATGTATAGCCCCA-3' and 
5'-TTTAATCCACAGCTAATGAAAGCC-3', respectively. The PCR conditions were 4 min 
at 95 ºC, then 35 cycles of 30s at 95 ºC, 1 min at 56 ºC, and 1 min at 72 ºC, and finally an 
elongation step at 72 ºC for 7 min. A 170 bp product was amplified and aliquots of 5 μl of the 
PCR mixture were immediately digested for one hour at 37°C with 10 units of the restriction 
enzyme NlaIII, followed by electrophoresis on 3% agarose gel, containing ethidium bromide. 
The PON1-55M allele contains a restriction site for NlaIII, yielding fragments of 44 and 126 
bp. This restriction site is not present in the PON1-55L allele (Figure 6.1a). To detect the 
Q192R substitution by PCR, the forward and reverse primers 5'-
TATTGTTGCTGTGGGACCTGAG -3' and 5'-CACGCTAAACCCAAATACATCTC -3' 
were used, respectively. The annealing temperature for this PCR was 1 min at 54 ºC, with 
remaining similar PCR conditions as described above. The restriction enzyme AlwI was used 
to discern the PON1-192Q and PON1-192R alleles (99 bp product), because the PON1-192R 
allele contains a restriction site for ALWI, yielding fragments of 33bp and 66bp (Figure 6.1b). 
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Figure 6.1. Identification of PON1 polymorphisms using restriction fragment length 
polymorphism analysis. Electrophoresis patterns of PCR fragments after digestion with NlaIII 
for the L55M polymorphism (a) and after digestion with AlwI for the Q192R polymorphism 
(b). M: 100 bp marker, lanes 1: homozygosity for the common allele, lanes 2: heterozygosity, 
lane 3: homozygosity for the variant allele. The sizes of the PCR fragments are indicated by 
arrows.  
 
 
Statistical analyses 
Data were analysed using SPSS version 11.0. Differences in the baseline characteristics of 
patients and controls were estimated with Fisher Exact test and Student’s t-test. Chi-square 
statistics was used to estimate differences in the presence of allele frequencies in PON1-55 
and PON1-192 among the different study groups. When one of the genotypes had expected 
counts less than five, the Chi-square test may not be appropriate, and in that case we used 
Fisher Exact test. Odds ratios (OR) with 95% confidence interval (95% CI) were calculated 
by logistic regression analysis for the allele frequencies in PON1-55 and PON1-192, taking 
into account confounding factors such as age, gender and smoking habits. 
We compared the allele frequencies and genotypes of ACP patients to those of alcoholic 
controls in order to correct for alcoholism. 
The distribution of the PON1-55 and PON1-192 allele frequencies of the control population 
was tested for the Hardy-Weinberg equilibrium. 
Finally, we examined the co-occurrence of alleles encoding the more active PON1 enzymes 
(PON1-55L and PON1-192R) in CP patients and control subjects, using Spearman rank 
correlation test. 
 
RESULTS 
 
Characteristics of patients and controls 
Characteristics of patients with CP and healthy controls are denoted in Table 6.1 There is a 
significant difference in gender between patients and healthy controls, with more females in 
the latter group (P < 0.05; Table 6.1). 
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As HCP patients develop the disease at a younger age than the other subgroups, their mean 
age was lower. The mean age of ACP patients was higher than that of the alcoholic control 
group (P < 0.05; Table 6.1). 
Although data on smoking habits was only available from a limited number of subjects, 
significantly more ACP patients smoked compared to healthy controls (P < 0.05; Table 6.1). 
 
Table 6.1. Main characteristics of patients with chronic pancreatitis and controls 
 
 
Characteristics 
HCP                  ACP                 ICP                All patients         Controls            Alc. controls 
 
n 
 
Gender 
       Male/Female  
        
Age (years) 
      Mean ( SD) 
 
Smoking 
       Yes/No 
       Unkown 
 
23                     137                   76                   236                     113                   93 
 
 
9/14                  106/31*            37/39*             152/84*               43/70                64/29 
 
 
38(21)*            51(9)**               48(17)           49(14)                46(16)              43(11) 
 
 
8/9                    91/7*                31/11             130/27               67/46                84/9 
6                       39                     34                   79                      0                       0 
HCP: Hereditary Chronic Pancreatitis; ACP: Alcoholic Chronic Pancreatitis; ICP: Idiopathic 
Chronic Pancreatitis; Alc.controls: Alcoholic control subjects; *: P-values < 0.05 as compared 
to normal control group; **: P-values < 0.05 as compared to alcoholic control group. 
 
 
Genotyping 
There are no statistical differences in the distribution of the homozygous PON1-55LL 
genotype, the homozygous PON1-55MM genotype or the heterozygous PON1-55LM 
genotype among patients with HCP, ACP, ICP or all CP patients versus the healthy control 
subjects (Table 6.2), and ACP patients versus alcoholic controls (Table 6.3). The frequencies 
of the PON1-55L and PON1-55M alleles in the different patient and control groups, do not 
demonstrate any statistical difference either (Tables 6.4 and 6.5)  
Tables 6.2 and 6.3 also present the observed distribution of PON1-192 genotypes in both 
control groups and the subgroups of patients with chronic pancreatitis of different origin. 
There is no statistical difference in the frequency of the PON1-192 polymorphism among 
patients with HCP, ACP, ICP or all CP patients versus the healthy control subjects, and in 
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ACP patients versus alcoholic controls. However, we detected a strong tendency of a higher 
frequency of the PON1-192QQ genotype in ICP patients. 
In accordance with the genotype distribution of PON1-192, a higher frequency of the PON1-
192Q allele and lower frequency of the PON1-192R allele is seen in ICP patients (Table 6.4). 
An estimated OR, adjusted for age, gender and smoking habits, showed a significant higher 
risk for ICP for individuals bearing the PON1-192Q allele (OR = 1.5, 95% CI: 1.02-2.5). The 
PON1-192 allele frequencies in the other patient and control groups did not demonstrate any 
statistical difference (Tables 6.4 and 6.5). 
For both polymorphisms in the PON1 gene, the distribution of the allele frequencies among 
the control population was separately tested and found to be in Hardy-Weinberg equilibrium. 
In addition, the co-occurrence of PON1-55 and PON1-192 polymorphisms was examined and 
a negative association was found in both the CP patient and control group (rs = -0.33, P < 
0.001 and rs = -039, P < 0.001, respectively). Thus, the PON1-55M and PON1-192Q alleles, 
both encoding ‘low’ enzyme activity, appear rather together. However, there was no statistical 
difference in the distribution of this combination of alleles between CP patients and healthy 
controls (P = 0.27). 
 
Table 6.2. Paraoxonase 1 genotype distribution in patients with chronic pancreatitis and 
healthy controls 
 
Genotype 
HCP                    ACP                    ICP                   All patients            Controls 
(n=21/23)¶          (n=137/122)¶       (n=73/76)¶        (n=231/221)¶         (n=113/111)¶  
♦ PON1 55 
            LL   
            LM  
            MM  
           P-value  
 
♦ PON1 192 
            QQ 
            QR  
            RR 
            P-value     
 
6 (29%)              58 (42%)            33 (45%)           97 (42%)               48 (42%) 
11 (52%)            62 (45%)            30 (41%)           103 (45%)             56 (50%) 
4 (19%)              17 (13%)            10 (14%)           31 (13%)               9 (8%) 
0.21                    0.49                    0.34                   0.31 
 
 
15 (65%)            65 (53%)            53 (70%)           133 (60%)             60 (54%) 
7 (30%)              49 (40%)            19 (24%)           74 (34%)               44 (40%) 
1 (4%)                8 (7%)                5 (7%)               14 (6%)                 7 (6%) 
0.63                    0.99                    0.07                   0.53     
HCP: Hereditary Chronic Pancreatitis; ACP: Alcoholic Chronic Pancreatitis; ICP: Idiopathic 
Chronic Pancreatitis; *: P-values, estimated with Chi-square test or with Fisher exact test, 
when cells have expected counts less than 5.  ¶: number of subjects successfully genotyped for 
the PON 55 / PON 192 polymorphisms; in both control and patient groups some data are 
missing because of insufficient amount of DNA or unsuccessful RFLP-PCR. 
 
 106
 
 
 
Table 6.3. Paraoxonase 1 genotype distribution in patients with alcoholic chronic pancreatitis 
and alcoholic control subjects 
 
Genotype 
ACP                      Alc.Controls 
 (n=137/122)¶        (n=89/87)¶ 
♦ PON1 55 
            LL   
            LM  
            MM  
           P-value  
 
♦ PON1 192 
            QQ 
            QR  
            RR 
            P-value            
 
58 (42%)             36 (40%) 
62 (45%)             46 (52%) 
17 (13%)             7 (8%) 
0.46 
 
 
65 (53%)            54 (62%) 
49 (40%)            29 (33%) 
8 (7%)                4 (5%) 
0.44  
ACP: Alcoholic Chronic Pancreatitis; Alc.Controls: alcoholic control subjects; *: P-values, 
estimated with Chi-square test or with Fisher exact test, when cells have expected counts less 
than 5. ¶: number of subjects successfully genotyped for the PON 55 / PON 192 
polymorphisms; in both control and patient groups some data are missing because of 
insufficient amount of DNA or unsuccessful RFLP-PCR. 
 
 
Table 6.4. Allele frequencies of Paraoxonase1 in patients with chronic pancreatitis and 
healthy controls 
 
Allele 
HCP                       ACP               ICP                        All CP                Controls 
 (n=42/46)¶      (n=274/244)¶      (n=146/152)¶           (n=462/442)¶      (n=226/222)¶      
♦ PON1 55 
             L   
             M              
           
            OR (95%CI) 
             
♦ PON1 192 
             Q 
             R              
              
            OR (95%CI)  
 
0.55                   0.65                     0.66                     0.64                    0.67                   
0.45                   0.35                     0.34                     0.36                    0.33          
                                                                                                                                       
0.6 (0.3-1.2)      0.8 (0.6-1.3)        1.0 (0.6-1.6)        1.1 (0.7-1.6)        
 
 
0.80                   0.73                     0.82                     0.77                   0.74                    
0.20                   0.27                     0.18                     0.23                   0.26   
                                                                                                                                                
1.6 (0.7-3.6)      0.9 (0.6-1.4)        1.5 (1.02-2.5)      1.1 (0.8-1.7)    
HCP: Hereditary Chronic Pancreatitis; ACP: Alcoholic Chronic Pancreatitis; ICP: Idiopathic 
Chronic Pancreatitis; OR: Odds Ratio; 95% CI: 95% Confidence Interval with adjustment 
made for age, gender and smoking by logistic regression. ¶: number of subjects successfully 
investigated for PON 55 / PON 192 polymorphisms; in patient and control groups some data 
are missing because of insufficient amount of DNA or unsuccessful RFLP-PCR. 
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Table 6.5. Allele frequencies of Paraoxonase 1 in patients with alcoholic chronic pancreatitis 
and alcoholic control subjects 
 
Allele 
ACP                    Alc Controls 
(n=274/244)¶       (n=178/174)¶        
♦ PON1 55 
             L   
             M               
              
            OR (95%CI) 
             
♦ PON1 192 
             Q 
             R  
                         
            OR (95%CI)         
 
0.65                     0.66                         
0.35                     0.34      
                       
1.0 (0.6-1.6)   
 
 
0.73                     0.79          
0.27                     0.21      
    
0.8 (0.5-1.4)  
ACP: Alcoholic Chronic Pancreatitis; Alc Controls: alcoholic control subjects; OR: Odds 
Ratio; 95% CI: 95% Confidence Interval with adjustment made for age, gender and smoking 
by logistic regression. ¶ : number of subjects successfully investigated for the PON 55 / PON 
192 polymorphisms; in both control and patient groups some data are missing because of 
insufficient amount of DNA or unsuccessful RFLP-PCR. 
 
 
DISCUSSION 
 
PON1 can offer protection against some xenobiotic chemicals and endogenous toxins and is 
proposed to protect against oxidative damage [16,27-32]. Genetic variations that may reduce 
expression or activity of this enzyme are of toxicological and physiological importance and 
are frequently associated with a variety of diseases. Cellular injury generated by xenobiotics 
or endogenous toxins might also play a role in the aetiology of CP [13,33,34].  
In the present study, we evaluated the possible association between PON1 genotypes and the 
susceptibility to CP, by studying the PON1-55 and PON1-192 polymorphism rates in both 
patients with CP and controls. 
We found that the PON1-192Q allele occurs significantly more frequent among patients with 
idiopathic CP as compared to hereditary- or alcoholic CP patients or healthy controls. 
Frequencies of the genetic polymorphisms in PON1-55 in Caucasian healthy control subjects 
were not different to those in CP patients. These results indicate that the PON1-192Q allele 
might be a risk factor for ICP and support the hypothesis that persistent oxidative stress may 
play a role in the development and maintenance of the disease. Considering the PON1-192Q 
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allele is encoding the ‘low’ enzyme activity, an imbalance of ROS-generating and ROS-
scavengic processes might lead to molecular and cellular damage of especially acinar cells, 
and might initiate auto-digestion of the pancreas. 
The frequency of the PON1-55M allele was 36% in CP patients compared to 33% in the 
control subjects. This is comparable to the frequencies (36%-43%) reported in Caucasian 
control subjects by several other groups [15]. The frequency of the PON1-192R allele was 
estimated at 18% in patients with ICP, 27% in ACP, 20% in HCP and 26% in healthy 
controls. Previous studies demonstrate frequencies of 26%-33% in Caucasian healthy controls 
[35], and these data are in excellent agreement with our results from the control group. Since 
this is the first study investigating the PON1 polymorphisms in a CP cohort, allele frequencies 
found cannot be compared to findings by others in such patients. However, numerous recent 
studies have investigated the association between PON1 polymorphisms and coronary artery 
diseases or ischemic stroke in the Caucasian population. Some of these studies showed an 
enrichment of the PON1-192R allele in the patient group [36-39], while others reported 
similar allele frequencies in patients and controls [40-43]. More recently, Oliveira et al. 
showed that the PON1-55M allele, with lower enzyme activity, protects against coronary 
artery disease [23]. These data indicate that the capacity of PON1 to prevent LDL from 
oxidative modification, which inversely correlates with efficiency to hydrolyse paraoxon, 
might contribute to susceptibility of coronary artery disease. 
Our findings in CP patients are consistent with data suggesting that PON1 acts as an 
important guard against cellular damage by oxidative stress, since ICP patient are bearing 
more often the low activity (PON1-192Q) allele. The higher enzyme activity encoded by the 
PON1-192R allele might better protect against pancreatitis by more efficient detoxification of 
reactive compounds.  
PON1 hydrolyzes organophosphates as well as dietary and environmental lactones, but also a 
number of commonly used drugs such as the cholesterol lowering HMG-CoA reductase 
inhibitors contain lactones that are metabolised by PON1. Although, the PON1-192R allele 
generally encodes a faster enzyme than the PON1-192Q allele, this does not apply to all 
PON1 substrates [44,45]. Furthermore, the actual antioxidant capacity of PON1 does not 
necessarily correspond to the values expected according to the PON1 genotype, because 
PON1 expression levels are dependent on several factors and might show considerable 
variation between individuals, even those bearing the same genotype [46].  
Since we are lacking information on dietary habits, medication etc. from our study 
populations, our findings have to be viewed in the perspective of this potential limitation. In 
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this study, we did adjust for age, gender and smoking habits as far as these data were 
available. In order to correct for alcoholism, we compared the genotypes of ACP patients to 
those of alcoholic controls.  
In summary, we demonstrate an under-representation of the “fast” PON1-192R allele in 
patients with idiopathic CP, which might suggest that low PON1 enzyme activity, is a risk 
factor for idiopathic CP. 
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ABSTRACT 
 
Background: The cause of chronic pancreatitis (CP) remains unknown. However, oxidative 
stress might play a role, recent animal studies have further demonstrated this by showing that 
oxygen free radicals contribute to the pathogenesis of experimental pancreatitis. In the present 
study, we assessed the levels of antioxidant capacity and oxidative damage in blood of CP 
patients in comparison with those in healthy control subjects, by using several different 
analytical techniques. 
Methods: Thirty-five patients with CP and 35 healthy controls with a similar age- and gender 
distribution and similar smoking habits were investigated prospectively by assessment of 
plasma levels of cysteine, homocysteine, cysteinylglycine and glutathione, ferric reducing 
ability of plasma (FRAP; i.e. antioxidant capacity), levels of protein carbonyls and 
thiobarbituric acid reactive substances (TBARS). In addition, we evaluated the production of 
reactive oxygen species (ROS) in whole blood, either in absence or presence of the 
stimulators phorbol 12-myritate 13-acetaat (PMA) or serum-treated zymosan (STZ). 
Results: Homocysteine concentrations were not different between CP patients and healthy 
control subjects, whereas cysteine, homocysteine and glutathione levels were significantly 
lower in CP patients. In addition, the non-enzymatic antioxidant capacity (FRAP) was 
significantly lower in CP patients, which correlated with the amount of oxidative protein 
(protein carbonyls)- and lipid damage (TBARS), which were both significantly higher in CP 
patients. The ROS production in whole blood, in response to stimulation with PMA, 
demonstrated a strong tendency towards an increased radical production in CP patients, 
whereas STZ-induced or non-stimulated were not statistically different between CP patients 
and a healthy control group.  
Conclusions: Our results, indicate a lowered antioxidant capacity and increased oxidative 
damage in CP patients, suggesting that oxidative stress might contribute to the pathogenesis 
of chronic pancreatitis, which may be a rationale for intervention with antioxidant therapy. 
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INTRODUCTION 
 
Chronic pancreatitis (CP) is a progressive irreversible inflammatory disease that eventually 
leads to an impaired exocrine and/or endocrine function of the pancreas [1-4]. Although most 
cases have been attributed to alcohol abuse, the underlying causes of CP appear to be multi-
faceted, including environmental as well as genetic factors. So far, we do not completely 
understand the pathogenesis of CP [5]. Different hypotheses have been proposed, including 
the contribution of oxidative stress of endogenous origin or chemical stress by environmental 
or lifestyle related xenobiotics [6-10]. There is growing recognition that an imbalance 
between reactive oxygen species (ROS) producing and ROS scavenging processes leads to the 
damage of pancreatic acinar cells, initiating auto-digestion of the entire pancreas. This insight 
is suggested by data from experimental and clinical studies [11-14]. Oxidative stress might be 
important in the pathogenesis of ethanol-induced pancreatic injury, although radiation, 
exposure to cigarette smoke, medication or trauma may stimulate the generation of free 
radicals, which subsequently may result in damage of lipids, proteins or nucleic acids. 
Activation of (enzymatic) antioxidative defence has been described in pancreatic disease 
independent of its origin [15]. Glutathione and cysteine are important mediators in the 
defence against oxidative stress and both molecules play a key role in the maintenance of 
cellular thiol redox status. Therefore, in the present study the concentrations of glutathione, 
cysteine and other thiols were measured in blood plasma of patients with CP and healthy 
control subjects. In addition, we also measured the non-enzymatic antioxidant capacity by 
applying the ferric reducing ability of plasma (FRAP) assay in patients with CP and in healthy 
controls. Further assessment of the level of oxidative stress was performed by measuring the 
concentrations of protein carbonyls in plasma in order to determine the amount of oxidative 
protein damage. As an indicator of lipid peroxidation we established the concentrations of 
thiobarbituric acid-reactive substances (TBARS). Finally, we investigated the generation of 
ROS by chemiluminescence in whole blood of both patients and controls. 
 
METHODS 
 
Subjects 
The study was approved by the local medical ethical review committee and all subjects gave 
their written informed consent. This study was conducted at the Department of 
Gastroenterology of the University Medical Centre Nijmegen, the Netherlands and all 
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subjects studied were Caucasians of Dutch extraction. A total of 35 consecutive CP patients 
were recruited between January 2004 and June 2004 at the out-patient clinic of the 
department. In 29 patients an alcohol-related etiology was indicated (ACP), the remaining 6 
CP patients had a family history of CP (HCP). The clinical diagnosis of CP was based on one 
or more of the following criteria: presence of typical complaints (recurrent upper abdominal 
pain, radiating to the back, relieved by leaning forward or sitting upright and increased after 
eating); suggestive radiological findings, such as pancreatic calcifications or pseudocysts, and 
pathological findings (pancreatic ductal irregularities and dilatations) revealed by endoscopic 
retrograde pancreaticography or magnetic resonance imaging of the pancreas before and after 
stimulation with secretin. ACP was diagnosed in patients who consumed more than 60 g 
(females) or 80 g (males) of ethanol per day for more than two years before they were 
diagnosed, during their treatment they all quit drinking alcohol. HCP was diagnosed based on 
the presence of two first-degree relatives or three or more second-degree relatives in two or 
more generations, suffering from recurrent acute pancreatitis or chronic pancreatitis for which 
there was no precipitating factor. 
For comparison, we collected a control group consisting of 35 healthy subjects. We recruited 
our healthy controls by advertisement in a local paper and did not apply any monetary 
incentive for the controls to participate. 
 
Analysis of thiols 
Samples of blood were taken by venapuncture into EDTA tubes. Whole blood was 
centrifuged at 1,500xg for 10 min within 1 hour after collection and plasma was stored at –30 
°C until analysis. Concentrations of the thiols cysteine, homocysteine, cysteinylglycine and 
glutathione (the sum of reduced-, oxidised- and protein-bound thiol) in plasma were 
quantified using high performance liquid chromatography (HPLC) with fluorescent detection, 
essentially as described by Fortin et al. [16] and modified by Raijmakers et al. [17]. Thiol 
levels were calculated using four-point calibration curves for each thiol, which were run in 
parallel with the samples, and values were expressed in μmol/L. 
 
Analysis of FRAP 
The antioxidant capacity in blood plasma was measured using the Ferric Reducing Ability of 
Plasma (FRAP) assay, according to the method of Benzie and Strain [18]. The reduction of 
ferric to ferrous ion at low pH causes a coloured ferrous-tripyridyltriazine complex to be 
formed. Absorbance changes are linear over a wide concentration range with antioxidant 
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mixtures, including plasma. FRAP values were obtained using a seven-point calibration curve 
of known amounts of Fe2+ and were expressed in mmol Fe2+/L. 
 
Analysis of protein carbonyls 
The amount of oxidative protein damage, as marker for oxidative stress, was determined 
using an Enzyme Linked Immunosorbent Assay (ELISA) for estimation of protein carbonyls 
in body fluids, as essentially described by Buss et al [19] and adapted by Zusterzeel et al [20]. 
Samples were incubated with dinitrophenylhydrazine, then adsorbed to wells of an ELISA 
plate before probing with a commercial antibody raised against protein-conjugated 
dinitrophenylhydrazine. The binding of biotin-conjugated primary antibody was then 
quantified after incubation with streptavidin-biotinylated horseradish peroxidase and staining 
with o-phenylenediamine. Calibration took place using oxidised and fully reduced albumin, 
and carbonyl levels were expressed in nmol/mg protein. 
 
Analysis of TBARS 
Thiobarbituric acid-reactive substances (TBARS), mainly malondialdehyde (MDA), in 
plasma were evaluated by recording the fluorescence spectrum between 500 and 600 nm on a 
Shimadzu RFF-5000 spectrofluorometer, of the thiobarbituric acid-malonaldehyde complex, 
as described by Conti et al. [21]. Levels of TBARS were expressed as μmol MDA/L. 
 
Analysis of ROS 
ROS production in whole blood was evaluated using Luminol- enhanced chemiluminescence, 
as measured in an automated LB96V Microlumat Plus Luminometer (EG & G Berthold, 
Belgium). Briefly, the signal-amplifying molecule Luminol reacts with oxygen species 
(mainly superoxide anion) generated by neutrophils in whole blood, to produce an excited 
state intermediate that, emits light as it returns to its ground state. ROS production was 
determined in the absence of a cellular stimulator, as well as in the presence of either a 
receptor dependent (serum-treated zymosan, STZ) or a receptor-independent stimulus 
(phorbol 12-myritate 13-acetaat, PMA). Freshly obtained heparinized blood was 1:100 diluted 
in HBSS containing 1 mM calcium. Two hundred μl of this diluted blood was added to each 
well of a 96 wells plate. In addition, reaction mixtures contained (final concentrations:) 
0.045% bovine serum albumine (BSA), 0.83 mM Luminol and either 0.5 μg/ml STZ, 1 mg/ml 
PMA or no stimulating agents. As an internal positive control for the luminescence process, 
samples of 0.1% ammonium persulphate (APS) in phosphate buffered solution (PBS) were 
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run simultaneously. Chemiluminescence was monitored every 60 sec for 1 hour. EDTA 
blood, taken together with the heparinized blood samples, was tested for leukocyte counts and 
differentiation, in order to be able to adjust the chemiluminescence produced during one hour 
(‘area under the curve’) in relative light units  (RLU) per cell for neutrophil counts. All 
measurements were performed in quadruplicate and corrected for background values (absence 
of a stimulus). 
Opsonized zymosan particles were prepared by incubation of STZ with pooled human serum 
for 30 min at 37 °C, as described before [22]. These particles were then washed twice in PBS 
and finally suspended at 12.5 mg/ml in PBS. 
 
Statistics 
Data were analysed using SPSS version 12.0. Differences in the baseline characteristics of 
patients and controls were estimated with Fisher Exact test and Student’s t-test. The Mann-
Witney U-test was used to estimate differences in biochemical parameters between the patient 
and control population in a non-parametrical manner. Differences were considered significant 
if P < 0.05. 
 
RESULTS 
 
Characteristics of patients with CP and healthy controls are denoted in Table 7.1. The mean 
age of the CP patients was 51 years (range 25 to 74) and was not significantly different from 
the healthy controls (45 years; range 27 to 68). There was no significant difference in the 
distribution of gender between CP patients and healthy control subjects. Smoking habits 
between CP patients and healthy controls were not different; 66% of the patients compared to 
63% of the control subjects smoked or stopped smoking within the last 5 years.  
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Table 7.1. Main characteristics of patients with chronic pancreatitis and healthy controls 
 
Characteristics 
CP patients           Controls 
 
n  
 
Gender 
      Male/Female 
 
Mean age 
(years;range) 
 
Smoking 
      Yes/No 
 
35                            35 
 
 
17/18                       18/17 
 
 
51(25 to 74)         45 (27 to 68) 
 
 
23/12                       22/13 
CP: chronic pancreatitis 
 
The measures for oxidative stress in CP patients and healthy controls, being plasma 
concentrations of cysteine (cys), homocysteine (Hcys), cysteinylglycine (CGS) and 
glutathione (GSH), the plasma antioxidant capacity (FRAP), plasma levels of protein 
carbonyls and TBARS and chemoluminescense in whole blood are depicted in Table 7.2. 
Plasma concentrations of the antioxidative thiols to wit, cysteine, cysteinylglycine and 
glutathione were significantly lower in CP patients as compared to corresponding values in 
the controls (P = 0.021, P = 0.003 and P = 0.048, respectively). Plasma levels of 
homocysteine were similar in both groups. The antioxidant capacity as measured by the 
FRAP assay was also significantly lower in CP patients as compared to the healthy control 
subjects (P < 0.001). Levels of both protein carbonyls and TBARS were significantly higher 
in CP patients as compared to healthy controls (P < 0.001). Chemiluminescence of diluted 
whole blood of CP patients and controls was not different, although a strong trend towards an 
increased ROS production after stimulation with PMA was detected (P = 0.058). As expected, 
spontaneous generation of ROS, i.e. in the absence of a stimulus, was less than 10% of the 
amount of ROS measured in response to the stimuli PMA and STZ. Leukocyte counts and 
differentiation were within the ranges considered normal at our hospital. Values obtained with 
either assay were not different for patients with ACP and HCP. 
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Table 7.2. Thiol plasma concentrations, FRAP antioxidant capacity, protein carbonyl plasma 
levels, TBARS plasma levels and ROS production in whole blood of patients with CP and 
controls 
 
Measures for oxidative stress 
CP patients                             Controls 
 
Cys  (μmol/L) 
Hcys (μmol/L) 
CGS (μmol/L) 
GSH (μmol/L) 
 
FRAP (mmol Fe2+/L) 
 
Carbonyls (nmol/mg protein) 
 
TBARS (μmol/L) 
 
ROS production (RLU/104 cells) 
    PMA-stimulated 
    STZ-stimulated 
 
225 (124-314)*               249 (212-328) 
13.6 (5.0-38.2)                         12.7 (0.2-27.8) 
34.8 (23.5-124)*                      39.3 (25.2-56.7) 
7.5 (2.4-18.5)*                         8.9 (3.5-16.1) 
 
0.75 (0.31-1.73)*                     0.99 (0.69-1.57) 
 
0.32 (0.02-1.47)*                     0.04 (0.01-0.07) 
 
4.98 (0.23-27.79)*                   0.35 (0.04-0.68) 
 
 
40 (1-83)           33 (1-87) 
124 (11-266)           111 (9-2130) 
Data are presented as median (range); * = P-value < 0.05; Cys: cysteine; Hcys: homocysteine; 
CGS: cysteinylglycine; GSH: glutathione; FRAP: ferric reducing ability of plasma; TBARS: 
thiobarbituric acid-reactive substances; ROS: reactive oxygen species; PMA: phorbol 12-
myritate 13-acetate; STZ: serum treated zymosan. 
 
 
DISCUSSION 
 
Alcohol abuse is regarded as a major risk factor for the development of CP. However, the 
exact mechanism behind the effect of alcohol remains unknown. Some evidence obtained by 
animal studies, suggests that metabolism of ethanol catalysed by cytochrome P4502E1 
(CYP2E1) may contribute to oxidative stress in the pancreas during chronic alcohol 
consumption [14]. Trauma, exposure to radiation, cigarette smoke, medication or other toxins 
generating free radicals also may increase the amount of oxidants. In the present study, we 
assessed the antioxidant capacity and levels of oxidative damage in CP patients as compared 
with healthy controls by means of several analytical techniques that are known to measure 
various components that together constitute oxidative stress. The major observations were that 
plasma concentrations of some thiols, having antioxidant properties, were significantly lower 
in CP patients. Likewise the non-enzymatic antioxidant capacity as measured by the FRAP 
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assay, is significantly lower in CP patients compared to healthy control subjects. This inferior 
antioxidant capacity in CP patients parallels significantly increased amounts of oxidative 
protein- and lipid damage, whereas the generation of ROS in whole blood did not show a 
statistically significant difference between CP patients and a healthy control group, with a 
similar age- and gender distribution and smoking habits. Our results clearly indicate that 
oxidative stress is present in patients with CP and that this eventually might contribute to the 
initiation and maintenance of inflammation in CP, as has been previously suggested 
[12,14,23-26]. 
 
Thiols such as cysteine and glutathione play an essential role as antioxidant, and are involved 
in protein synthesis, redox sensitive transduction signalling, cell growth and proliferation, 
xenobiotic metabolism and in immune regulation [27]. Glutathione is conjugated to many 
xenobiotics and is essential for the optimal functioning of numerous enzymes and hence 
crucial for cell viability. Decreased levels of glutathione in plasma have been reported, but 
paradoxically also increased glutathione levels may be found as a result of overshoot after 
enhanced synthesis due to oxidative stress or conjugation of toxic compounds, as has been 
shown in different disorders [28-30]. The synthesis of glutathione takes place in two steps that 
are catalysed by γ-glutamylcysteine and glutathione synthetase, respectively [31]. 
Homocysteine can be converted either to cysteine or remethylated to methionine [31]. We 
found significantly lowered plasma concentrations of cysteine, cysteinylglycine and 
glutathione in CP patients as compared to healthy controls, whereas the control values 
measured here can be considered normal for the Dutch population [17]. We found no elevated 
concentrations of homocysteine in CP patients, however homocysteine does not always act as 
an antioxidant, moreover elevated plasma concentrations of homocysteine are positively 
associated with an increased risk of cerebral, coronary or peripheral vascular diseases [32]. 
In parallel with the lower plasma concentrations of the antioxidative thiols, the FRAP assay 
also demonstrated a significantly lowered antioxidant capacity in CP patients. Since the 
FRAP assay does not measure sulfhydryl (SH)-containing antioxidants such as the thiols 
glutathione and cysteine, this indicates that other non-thiol related antioxidants are decreased 
in CP patients also. In patient with acute pancreatitis very low ascorbate concentrations in 
plasma have been described before [33,34]. 
Protein carbonyl derivates are generated by direct oxidative attack of proteins, or indirectly by 
lipid peroxidation products and therefore represent a good biomarker for general oxidative 
stress [35,36]. The lowered FRAP levels in CP patients are accompanied by high protein 
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carbonyl concentrations, indicating increased oxidative damage has occurred as a result of the 
lowered protective capacity as measured by FRAP. Former studies have demonstrated 
elevated plasma protein carbonyls in experimental animal models [37,38] and in humans with 
acute pancreatitis [39]. 
Unless properly scavenged, ROS may lead to lipid peroxidation, which represent an important 
manifestation of oxidative stress. Lipid peroxidation is initiated when free radicals interact 
with polyunsaturated fatty acids. For instance, in cell membranes this may result in a chain 
reaction forming lipid hydroperoxides. Analysis of TBARS in plasma is a widely used 
method for the estimation of lipid peroxidation. In accordance with the elevated levels of 
protein carbonyls and lowered antioxidant capacity, we found significantly increased plasma 
concentrations of TBARS in CP patients.  
The production of ROS, as measured in whole blood by the a chemiluminescence assay, was 
not significantly higher in CP patients as compared to healthy controls, although there was a 
strong trend of higher amounts of ROS generated after stimulation with PMA, however 
significance was not reached (PMA: P = 0.058). We used a Luminol-enhanced 
chemiluminescence assay in 100-fold diluted whole blood to study ROS generation of 
peripheral blood cells in a non-disturbed system. As expected, ROS generation in the absence 
of a stimulus in CP patients was low, and was not significantly different compared to the 
values in the healthy control group. The chemiluminescence measurements did not 
demonstrate a significantly increased ROS generation in CP patients, while the other 
analytical techniques applied here showed increased oxidative stress and oxidative damage in 
CP patients as compared to healthy control subjects. This clearly demonstrates that the 
oxidative damage in CP patients is caused by other reactive (oxygen) species than produced 
by the patient’s leucocytes. Since by far the most CP patients included in this study are 
alcoholics, the cause of oxidative damage may be mainly of exogenous origin. However, a 
contribution of oxidative stress of endogenous origin might also be possible, since we 
detected a strong tendency of ROS production in CP patients after stimulation with PMA. 
This PMA-induced respiratory burst is receptor-independent and not absolutely dependent on 
priming [40], whereas priming does moderately influence the STZ-induced respiratory burst 
[41]. We measured the ROS production in whole blood and it is known that during isolation 
of neutrophils, these cells often become primed [42]. 
The clinical importance of oxidative stress in human pancreatic disease was first suggested by 
Braganza et al. [43], and subsequently supported by data from other groups, showing 
increased levels of lipid hydroperoxides in pancreatic juice [9] and increased spontaneous 
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production of ROS by neutrophils [23,44]. In the present study, the assessment of oxidative 
stress in CP patients corroborates the hypothesis that oxidative stress leads to damage of 
pancreatic acinar cells, initiating auto-digestion of the entire pancreas.  
In summary, significant higher levels of products of oxidative damage (protein carbonyls and 
TBARS), correlating with decreased levels of cysteine, cysteinylglycine, glutathione and non-
enzymatic antioxidant capacity (FRAP) were found in CP patients as compared to healthy 
control subjects with no differences in age, gender and smoking habits. Thus, oxidative stress, 
defined as the imbalance between prooxidant and antioxidant capacity, is higher in CP 
patients, and this may justify further studies on intervention by antioxidant therapies, directed 
on prevention or treatment of this serious disease.  
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Chapter 8 
 
 
Summary and conclusions 
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Chronic pancreatitis (CP), a disease with an enormous personal and social impact, shortens 
life expectancy up to 10-20 years and remains a major source of morbidity in the world. It is a 
destructive inflammatory process that ends in total destruction of the pancreas and results in 
malabsorption of dietary nutrients, diabetes mellitus and severe abdominal pain. The origin of 
CP is mixed, with about 70% of the cases being attributed to alcohol abuse even though 95% 
of all alcoholics never develop CP. Approximately half a century ago, it was perceived that 
CP clusters in selected families, suggesting an inherited disease in these patients. By now 
there is universal recognition that multiple factors, including genetic factors, may ultimately 
lead to CP. Several genetic risk factors for CP have been identified recently. This thesis 
addresses a number of studies on genetic variations in detoxification enzymes and the risk for 
CP. In addition, the contribution of oxidative stress in CP is described. 
 
Chapter 1 provides a general introduction for this thesis and outlines the objectives. 
Objectives are 1) To investigate the association between polymorphisms in biotransformation 
enzymes and the development of chronic pancreatitis and 2) To further elucidate the role of 
oxidative stress in the pathogenesis of chronic pancreatitis. 
In Chapter 2 the GSTM1 null genotype is identified as a protective factor for alcoholic CP 
(ACP), since this genotype is significantly less common in patients with ACP, most 
pronounced in female ACP patients younger than 50 years, as compared to the other CP 
patients, healthy controls or alcoholic control subjects. In addition, we found no differences in 
the rates of GSTT1 and GSTP1 genotypes between CP patients and healthy controls. This 
suggests that GSTM1 null alcohol users, particularly young females, are less susceptible to 
CP. 
Since alcohol abuse is regarded as the major risk factor for CP it might be suggested that 
susceptibility for CP could be influenced by inter-individual variations in the activities of 
alcohol-metabolising enzymes. Therefore, we have focussed on the contribution of genetic 
variations in the main alcohol metabolising enzymes: alcohol dehydrogenases (ADHs) and 
cytochrome P450 2E1 (CYP2E1). Chapter 3 represents data suggesting that the risk of ACP 
might be associated with a genetic polymorphism in intron 6 of CYP2E1, whereas 
associations with other polymorphisms in CYP2E1 and ADH3 are lacking. This might point to 
a higher risk for ACP in individuals with chronic alcohol consumption and a slow microsomal 
ethanol oxidising genotype. 
In Chapter 4 the possible association between the predisposition for CP and genetic 
polymorphisms, associated with changes in enzyme activity and function, in three UDP-
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glucuronosyltransferase 1A isoenzymes that are potentially expressed in pancreatic tissue, is 
studied. However, the distribution of the various alleles of UGT1A1, UGT1A6 and UGT1A8 
did not differ between CP patients and healthy controls. It can be concluded that the presence 
of genotypes possibly associated with low detoxification activity of UGT1A1, UGT1A6 or 
UGT1A8 enzymes, do not predispose to CP. 
In contrast to an earlier study by Ockenga et al (Gastroenterology 2003; 124:1802-8), in 
Chapter 5 we demonstrate that genetic polymorphisms in UDP-glucuronosyltransferase 1A7 
do not predispose to the development of pancreatic cancer and pancreatitis, since frequencies 
of UGT1A7 genotypes did not differ between patients with acute or chronic pancreatitis as 
well as pancreatic adenocarcinoma and healthy alcoholics or control individuals. In addition, 
we detected two novel rare alleles, UGT1A7*10 and UGT1A7*11. We found evidence that 
PCR bias due to uneven allele amplification caused by a T to G transversion (-57T>G) 
located within the chosen primer sequence probably accounts for the different results as 
presented in a recent study by Ockenga et al. 
In Chapter 6 we demonstrate that genetic variations in paraoxonase (PON1), an antioxidant 
enzyme that is proposed to protect against cellular damage by oxidative agents, modify the 
risk for CP. We found an under-representation of the “fast” PON1-192R allele in patients with 
idiopathic CP, which might suggest that low PON1 enzyme activity is a risk factor for 
idiopathic CP. 
Chapter 7 demonstrates the contribution of oxidative stress in the aetiology of CP. The levels 
of thiols, important non-enzymatic antioxidants, were determined in plasma of CP patients 
and controls, as well as the corresponding levels of products of oxidative damage, which were 
found to be significantly higher and correlated with the decreased non-enzymatic antioxidant 
capacity. However, measuring the generation of ROS by a chemiluminescence assay, no 
significant higher oxidative stress in CP patients was found, albeit a tendency of more ROS 
production after stimulation with PMA was detected. 
 
In summary, we may conclude that genetic predisposition for CP might be partly the result of 
polymorphisms in detoxification enzymes, in particular the GSTM1 null genotype, which 
provides protection against ACP, most probably because some dietary CP protecting 
compounds can hardly be metabolized in individuals bearing this null genotype. Furthermore, 
the presence of the CYP2E1 intron 6 DD genotype, encoding a less efficient microsomal 
alcohol-metabolizing enzyme, might confer a higher risk of alcoholic CP. This might be 
attributable to either a delay of the formation of acetaldehyde, the highly toxic metabolite of 
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alcohol, and so permitting higher intake of alcohol, or a result of a higher pressure on the 
cytosolic ADH oxidizing system. It is possible that a shift from microsomal to cytosolic 
oxidation of alcohol might generate more damage to vital cellular systems. Moreover, 
presence of the PON1-192Q allele, resulting in partly deficient antioxidant and detoxification 
activity of this enzyme, might be a risk factor for idiopathic CP. Nevertheless, we failed to 
detect associations between CP and genetic polymorphisms in other biotransformation 
enzymes such as the UDP-glucuronosyltransferases. Apparently, genetic variations in these 
enzymes might not modify the risk for CP. 
Additionally, a lower antioxidant capacity and more oxidative damage was established in CP 
patients as compared to healthy controls, suggesting that oxidative stress might contribute to 
the pathogenesis of CP. 
In conclusion, we believe that molecular and genetic analyses for evaluation of pancreatic 
diseases will become important in future. Identification of key mutations in pancreatic-
associated genes will provide important information on risk of developing CP. Moreover, 
mutation detection will assist in early diagnosis and helps to determine the aetiology of CP. 
Besides, knowledge on specific polymorphisms will help understanding of gene-environment 
interactions and knowledge of functional consequences of gene defects may help developing 
new therapeutic interventions. Finally, identification of functional gene mutations for CP is 
important for patients who are seeking answers to the question “why” they have developed 
CP and will be of help in family planning decisions. This thesis is a start for the research at 
some genetic aspects of CP and might direct future research on the molecular mechanisms of 
chronic pancreatitis. 
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Chapter 9 
 
 
Samenvatting en conclusies 
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Chronische pancreatitis (CP), een ziekte met een enorme persoonlijke en sociale impact, 
verkort de levensverwachting met 10 tot 20 jaar en blijft een belangrijke bron van morbiditeit 
in de wereld. Het is een destructief ontstekingsproces gepaard gaande met hevige pijn in de 
buik, dat eindigt in totale destructie van de pancreas wat resulteert in malabsorptie van 
voedingsnutriënten en diabetes mellitus. De oorzaak van CP is verschillend, ongeveer 70% 
van de gevallen kan worden toegeschreven aan alcohol misbruik, hoewel 95% van alle 
alcoholisten nooit CP ontwikkelen. Ongeveer een halve eeuw geleden was het men 
opgevallen dat CP in bepaalde families voorkomt, wat suggereert dat het om een erfelijke 
ziekte gaat in deze patiënten. Inmiddels is het algemeen erkend dat meerdere factoren, 
inclusief genetische factoren, kunnen bijdragen aan het ontstaan van CP. Verscheidene 
genetische risicofactoren zijn voor CP in het recente verleden geïdentificeerd. Dit proefschrift 
beschrijft een aantal studies in hoeverre genetische variaties in ontgiftingsenzymen de kans op 
het krijgen van CP beinvloeden. Bovendien is de rol van oxidatieve stress in het ontstaan van 
CP onderzocht. 
 
Hoofdstuk 1 geeft een algemene introductie voor dit proefschrift en aan het eind van dit 
hoofdstuk wordt het doel geformuleerd. Dit is: 1) Onderzoek naar de rol van genetische 
variatie in biotransformatie enzymen bij het ontstaan van chronische pancreatitis en 2) Het 
bestuderen van de rol van oxidatieve stress in de pathogenese van chronische pancreatitis. 
In Hoofdstuk 2 is het GSTM1 nul genotype geïdentificeerd als een beschermende factor voor 
alcoholische CP (ACP). Dit genotype komt namelijk significant minder vaak voor bij 
patiënten met ACP, met name bij vrouwelijk ACP patiënten, jonger dan 50 jaar, in 
vergelijking met andere CP patiënten, gezonde controles en alcoholische controles. Hierbij 
vonden wij geen verschillen in de ratio van de GSTT1 en GSTP1 genotypen tussen CP 
patiënten en gezonde controles. Dit suggereert dat alcohol gebruikers met het GSTM1 nul 
genotype, in het bijzonder jonge vrouwen, minder gevoelig zijn voor CP. 
Aangezien alcoholmisbruik als de belangrijkste risicofactor voor CP wordt beschouwd, is het 
voorstelbaar dat de gevoeligheid voor CP beïnvloedt wordt door inter-individuele variaties in 
activiteit van alcohol-metaboliserende enzymen. Daarom hebben wij ons gericht op de 
bestudering van de genetische variabiliteit in alcoholdehydrogenase (ADH) en cytochroom 
P450 2E1 (CYP2E1) enzymen, als eventuele modulatoren van het risico voor CP. De data in 
Hoofdstuk 3 laten zien dat de kans op het krijgen van ACP geassocieerd zou kunnen zijn met 
een polymorfisme in intron 6 van CYP2E1, terwijl associaties tussen andere polymorfismen 
in CYP2E1 en ADH3 niet gevonden zijn. Dit zou kunnen wijzen op een hoger risico voor 
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ACP in individuen met chronisch alcohol gebruik en een langzaam CYP2E1 (microsomaal) 
ethanol oxiderend genotype. 
In Hoofdstuk 4 is het mogelijke verband bestudeerd tussen de predispositie voor CP en 
genetische polymorfismen in drie UDP-glucuronosyltransferase 1A enzymen, die 
geassocieerd zijn met veranderingen in enzymactiviteit en functie en die in pancreas weefsel 
aanwezig kunnen zijn. De verdeling van de verschillende allelen van UGT1A1, UGT1A6 en 
UGT1A8 verschillen echter niet tussen CP patiënten en gezonde controles. Dit betekent dus 
waarschijnlijk dat de mogelijke aanwezigheid van UGT1A1, UGT1A6 en UGT1A8 enzymen 
met een verlaagde activiteit geen extra risico oplevert voor het ontstaan van de ziekte CP. 
In tegenstelling tot een eerdere studie van Ockenga en anderen (Gastroenterology 2003; 124: 
1802-8), laat Hoofdstuk 5 zien dat polymorfismen in UDP-glucuronosyltransferase 1A7 niet 
predisponeren voor de ontwikkeling van pancreas adenocarcinomen en pancreatitis, omdat 
frequenties van UGT1A7 genotypen niet verschillen tussen patiënten met acute of chronische 
pancreatitis dan wel pancreas adenocarcinomen en alcoholische en gezonde controle 
individuen. Daarbij ontdekten we twee nieuwe, zeldzame allelen: UGT1A7*10 en 
UGT1A7*11. Bovendien vonden we sterke aanwijzingen dat een PCR fout door 
onregelmatige amplificatie, veroorzaakt door een substitutie van een T door een G (-57T>G), 
gelokaliseerd in de gekozen primer sequentie, de gevonden verschillen met die van een 
recente studie van Ockenga et al. kan verklaren. 
In Hoofdstuk 6 tonen we aan dat genetische variatie in paraoxonase (PON1), een antioxidant 
enzym waarvan men denkt dat het beschermt tegen cellulaire schade als gevolg van 
oxidatieve stress, het risico voor CP modificeert. We vinden een ondervertegenwoordiging 
van het ‘snelle’ PON1-192R allel in patiënten met idiopathische CP. Dit zou kunnen 
suggereren dat lage PON1 enzymactiviteit een risicofactor is voor het ontstaan van 
idiopatische CP. 
Hoofdstuk 7 beschrijft het aandeel van oxidatieve stress in de etiologie van CP. De bepaling 
van thiol concentraties (niet-enzymatische antioxidant capaciteit) in bloedplasma van 
patienten met CP en controles is beschreven. Bovendien werden er significant lagere 
hoeveelheden ‘producten van oxidatieve schade’ gemeten, wat overeenkwam met de 
verlaagde niet-enzymatische antioxidant capaciteit. Echter, meting van 
zuurstofradicaalproductie met behulp van een chemiluminescentie assay, laat niet significant 
meer oxidatieve stress zien in bloed van patienten met CP in vergelijking met controles, 
hoewel er wel een tendens van een hogere zuurstofradicaal productie zichtbaar was in 
patienten met CP, na stimulatie met PMA. 
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Samenvattend kunnen we concluderen dat genetische predispositie voor CP mede het gevolg 
kan zijn van polymorfismen in ontgiftingsenzymen. Het GSTM1 nul genotype biedt 
bescherming tegen ACP doordat waarschijnlijk dieetcomponenten met een beschermend 
effect niet of minder snel gemetaboliseerd kunnen worden door individuen met dit genotype. 
Voorts lijkt de aanwezigheid van het CYP2E1 intron 6 DD genotype, coderend voor een 
minder efficiënt microsomaal alcohol-metaboliserend enzym, een hoger risico voor het 
ontstaan van CP op te leveren. Dit kan waarschijnlijk toegeschreven worden aan een 
vertraging in de omzetting van ethanol naar aceetaldehyde, de meest toxische metaboliet van 
alcohol, waardoor er langere tijd een bepaald niveau van aceetaldehyde aanwezig blijft. En 
waardoor er een verhoogde druk op het ADH oxidatie systeem komt te staan. Het is ook 
mogelijk dat een verschuiving van het alcoholmetabolisme in de cel van het endoplasmatisch 
reticulum naar het cytoplasma meer schade aan vitale celsystemen genereert. Verder zien we 
dat het PON1-192Q allel, dat kan leiden tot een gedeeltelijk deficiënte antioxidant- en/of 
ontgiftingsactiviteit van dit enzym, een risicofactor kan zijn voor idiopatische CP. Nochtans 
zijn we er niet in geslaagd om associaties tussen genetische polymorfismen en het ontstaan 
van CP, in andere biotransformatie enzymen zoals UDP-glucuronosyltransferasen, aan te 
tonen. Kennelijk modificeren genetische variaties in deze enzymen het risico voor CP niet of 
nauwelijks. 
Verder is een verlaagde antioxidant capaciteit en meer oxidatieve schade in CP patiënten in 
vergelijking met gezonde controles aangetoond. Dit suggereert dat oxidatieve stress ook een 
aandeel heeft in de pathogenese van CP. 
We concluderen dat moleculaire en genetische analyses in de toekomst belangrijker zullen 
worden voor de vroeg-herkenning en dientengevolge snellere behandeling van patiënten met 
pancreas ziekten. Opsporing van belangrijke mutaties in pancreas-geassocieerde genen geeft 
belangrijke informatie over het risico dat een bepaald individu heeft met betrekking tot het 
ontstaan van CP. Bovendien helpt mutatieanalyse bij vroege diagnostisering en het bepalen 
van de etiologie van de CP. Specifieke mutatie analyse kan ook onze kennis over gen-
omgevingsinteracties en de functionele gevolgen van een gen defect vergroten en daardoor 
van groot belang zijn bij het ontwikkelen van nieuwe behandelingen. Tenslotte is het 
opsporen van een relevante genmutatie belangrijk voor patiënten die zoeken naar antwoord op 
de vraag ‘waarom’ ze CP hebben ontwikkeld en van groot belang zijn bij het nemen van 
beslissingen over gezinsuitbreiding. Dit proefschrift is een aanzet tot onderzoek naar 
verschillende genetische factoren die een rol zouden kunnen spelen bij het ontstaan van CP, 
om zo de moleculaire mechanismen van chronische pancreatitis te kunnen ontrafelen. 
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